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ACN  Acetonitrile 
ALM  Acral Lentiginous Melanoma 
ALR  Autophagic Lysosome Reformation 
AKT  v-Akt murine thymoma viral oncogene homolog 
ALDH  Aldehyde Dehydrogenase 
ANOVA Analysis of Variance 
ARID1/2 AT-Rich Interaction Domain 1 and 2 
ARL8B ADP Ribosylation Factor Like GTPase 8B 
ASAH1 N-Acylsphingosine Amidohydrolase 1 
ATG  Autophagy Related Genes 
BCL2  B-cell lymphoma 2 
BIRC7  Baculoviral IAP Repeat Containing 7 
BRAF  v-raf murine sarcoma viral oncogene homolog B 
BrdU  Bromodeoxyuridine 
BSA  Bovine Serum Albumin 
C6  6 Carbons 
CBE  Confutirol B Epoxide 
CCND1 Cyclin D1 
CCZ1 CCZ1 Homolog, Vacuolar Protein Trafficking And Biogenesis 
Associated 
CD  Cluster of Differentiation 
CERS  Ceramide Synthase 
CI-M6PR Cation Independent Manose 6 Phosphate Receptor 
CID/CAD Collision-Activated Dissociation/Decomposition 
CM  Conditioned Medium 
CMT2B Charcot-Marie-Tooth type 2B 
CNIO  Centro Nacional de Investigaciones Oncológicas 
CNS  Central Neural System 
COP9S Constitutive Photomorphogenic Subunit 9 
CORVET Class C CORe Vacuole/Ensosome Tethering Comples 
CPEB4 Cytoplasmic Polyadenylation Element Binding Protein 4 
CUBP1 CUGBP Elav-Like Family Member 1 
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CTS  Cathepsins 
DAPI  4,6-diamidino-2-phenylindole 
DEK  DEK Oncogene 
DMEM Delbucco´s Modified Eagle´s Medium 
DMSO  Dimethyl sulfoxide 
DN  Dominant Negative 
DRM  Detergent Resistant Membranes 
DTT  Dithiothreitol 
E1A  Adenovirus early region 1A 
EC  Endothelial Cells 
ECM  Extracellular Matrix 
EEA1  Early Endosome Antigen 1 
EGF  Epithelial Growth Factor  
EGFR  Epithelial Growth Factor Receptor 
ER  Endoplasmic Reticulum 
ERBB4 Erb-B2 Receptor Tyrosine Kinase 4 
ETV1  ETS Variant 1 
ESCRT Endosomal Sorting Complex Required for Transport. 
EZH2  Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit 
FACS  fluorescence-activated cell sorting 
FA  FA Lysis Buffer 
FASP  Filter Aided Sample Preparation 
FBS  Fetal Bovine Serum 
FDR  False Discovery Ratio 
FYCO1 FYVE and collected domain containing 1 
GAP  GTPase Activating Proteins 
GBA  Glucosylceramidase 
GDP  Guanosine Diphosphate 
GEF  Guanine Exchange Factor 
GNAQ  G Protein Subunit Alpha Q 
GO  Gene Ontology 
GSEA  Gene Set Enrichment Analysis 
GTP  Guanosine Triphosphate 
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H&E  Hematoxylin and Eosin 
HNSCC Head and Neck Squamous Cell Carcinoma 
HOPS  Homotypic fusión and Sorting Complex 
HRAS  v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
HRP  Horse Radish Peroxidase 
HSPA5 Heath Shock Protein A5 
IF  Immunofluorescence 
IAA  Indoleacetic Acid 
IgG  Immunoglobulin G 
IHC  Immunohistochemistry 
iTRAQ isobaric Tag for Relative and Absolut Quantification 
JNK  c-Jun N-terminal Kinases 
KEGG  Kyoto Encyclopedia of Genes and Genomes 
KIT  Proto-Oncogene Receptor Tyrosine Kinase 
LAMP  Lysosomal membrane protein 
LBPA  lysobisphosphatidic acid 
LC3  Microtubule-associated protein 1 light chain 3 
LC-MS/MS Liquid Chromatography Tandem-Mass Spectrometry 
LDLR  Low Density Lipoprotein Receptor 
LMN  Lentigo Malignant Melanoma 
LRP  Low density lipoprotein-Related Protein  
LRO  Lysosomal Related Organelle 
MAPK  Mitogen-Activated Protein Kinase 
MDM  Mouse double minute 2 
MEFS  Mouse Embryonic Fibroblasts 
MET Mesenchymal Epithelial Transition (MET) Proto-Oncogene 
MITF  Microphtalmia-associated Transcription Factor 
MM  Mucosal Melanoma 
MMP  Matrix Metalloproteinase 
MON1  MON1 Homolog A, Secretory Trafficking Associated 
miR  microRNA 
mRNA  messenger RNA 
MTP1-MMP Membrane Type Matrix Metalloproteinase 
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mTOR  mechanistic target of Rapamycin 
MSH  Melanocyte-Stimulating Hormone  
MVB  Multivesicular Body 
MYC  v-Myc Avian Myelocytomatosis Viral Oncogene Homolog 
NBD  Nitrobenzoxadiazole 
NEDD9 Neural Precursor Cell Expressed, Developmentally Down-
Regulated 9 
NES  Normalized Enrichment Score 
NF1  Neurofibromin 1 
NF-KB  Nuclear Factor Kappa-light-chain-enhancer of activated B cells 
NK  Natural Killer cells 
NM  Nodular Melanoma 
NRAS  Neuroblastoma RAS viral oncogene homolog 
NT  Non Treated 
OCR  Oxygen Consumption Rate 
OIS  Oncogene Induced Senescence 
ORP1L Oxysterol Binding Protein 
OS  Overall Survival 
OXPHOS Oxidative phosphorylation 
PBS  Phosphate Buffer Saline 
pH  Potential of Hydrogen 
PCR  Polymerase Chain Reaction 
PI3K  Phosphatidylinositol-4,5.biphosphate 3-Kinase 
PINK1  PTEN Induced Putative Kinase 1 
PPP6C Protein Phosphatase 6 Catalytic Subunit 
PTEN  Phosphatase and Tensin Homolog 
qPCR  quantitative Polymerase Chain Reaction 
RAB  Ras-related in brain 
RabGGT Rab Geranylgeranyl Transferasa 
RAC1  Rac Family Small GTPase 1 
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RILP  Rab7-interacting Lysosomal Protein 
RIP  Regulated Intramembrane Proteolysis 
RT  Room Temperature 
S1P  Sphingosine 1 Phosphate 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEM  Standard Error of estimate mean 
shRNA short hairpin RNA 
siRNA  small interfering RNA 
SLAC2  Slp Homolog Lacking C2 Domains A 
SLP2  Synaptotagmin-Like Protein 2 
SMPD1 Sphingomyelin Phosphodiesterase 1 
SNARE  Soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor 
ssGSEA single sample Gene Set Enrichment Analysis 
SSM  Superficial Spreading Melanoma 
STRING Search Tool for the Retrieval of Interacting Genes/Proteins 
TBC1D15 TBC1 Domain Family Member 15 
TCGA  The Cancer Genome Atlas 
TBC1D15 TBC1 domain family member 15 
TEM  Transmission Electron Microscopy  
TERT  Telomerase Reverse Transcriptase 
TGN  Trans Golgi Network 
TRP2  tyrosinase-related protein 2 
TP53  Tumor Protein P53 
TYR  Tyrosinase 
TYRP1 Tyrosinase-related protein-1 
UM  Uveal Melanoma 
USA  United States of America 
UVRAG UV irradiation Resistance-Associated Gene 
VGP   Vertical Growth Phase 
VPS34 Vacuolar Protein Sorting 34 
VSVG  Vesicular stomatitis virus glycoprotein 
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Melanoma is a prime example of an aggressive tumor that accumulates a plethora 
of changes in the transcriptome and the proteome. This accumulation of mutations 
makes this tumor the most aggressive form of skin cancer. The aggressive nature 
of this disease is shown by the fact that lesions of barely 2 mm in depth already 
bear a high metastatic potential. Our group has focused on lineage-specific 
oncogenic dependencies as a strategy to identify unique or melanoma-enriched 
proteins that distinguish this tumor from other cancer types. In particular, we 
previously identified a melanoma-specific rewiring of vesicular trafficking 
characterized by a cluster of lysosomal genes differentially expressed in 
melanoma compared with other 35 tumor types. Within this cluster, we 
demonstrated a dependency of melanoma cells on the small GTPase RAB7. 
Curiously, RAB7 levels were not constant during tumor progression: high levels 
favor proliferation, tuned-down expression of RAB7 was associated with an 
increased metastasis. Instead, downregulation of RAB27, another RAB protein 
also related to vesicular trafficking and regulated in a lineage-restricted manner 
in melanoma cells, inhibited melanoma metastasis 
  
Therefore, this PhD thesis was set to (1) Assess the differential impact of RAB7 
and RAB27 in vesicular trafficking, (2) Perform a global proteomic analysis of 
intracellular and secreted fractions of melanoma cell lines upon RAB7 and RAB27 
depletion and (3) to define functional differences RAB7 vs RAB27 in invasion and 
metastasis. To this end, we have observed how RAB7 and RAB27 have non-
equivalent roles in cell invasion in auto-and paracrine ways and we have 
performed a global proteomic analysis of cell extracts and conditioned medium 
upon RAB7 and RAB27 depletion that allowed us to identify a rewiring of the 
sphingolipid metabolism pathways upon RAB7 depletion towards ceramide 
production.  Moreover, analysis of the secretome allowed us to identify a cluster 
of lysosomal proteins specifically secreted. Within this cluster we identified LRP2, 
a transmembrane protein with unexpected prometastatic roles downstream 
RAB7  whose subcellular location is ceramide-enriched vesicles which are later 
secreted. Taken together, the results of this PhD thesis deepens the knowledge of 
vesicular trafficking in melanoma and establish a novel crosstalk between 
sphingolipid metabolism and vesicle trafficking modulators.
II. Summary/Presentación 
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En la actualidad, el melanoma cutáneo es una de las neoplasias más agresivas y se 
caracteriza por la manifestación de una masiva acumulación de cambios tanto a 
nivel transcripcional como proteómico. Esto confiere al melanoma una 
agresividad intrínseca, por la cual lesiones de una profundidad ínfima presentan 
un elevado potencial metastásico. Investigaciones recientes desarrolladas en este 
laboratorio, han dilucidado la relevancia de oncogenes de linaje celular específico 
como posibles reguladores oncogénicos. Concretamente, se ha identificado una 
regulación específica del tráfico vesicular en melanoma caracterizada por grupo 
de genes cuya función está referida al tráfico lisosomal, y cuya expresión en 
melanoma en comparativa frente a 35 tumores diferentes es diferencialmente 
elevada. Dentro de este agrupamiento de genes se demostró la dependencia que 
presentan las células de melanoma en referencia a la pequeña GTPasa de 
membrana RAB7. En particular, los niveles de RAB7 no se presentan constantes 
durante la progresión tumoral, sino que presentan una oscilación en su patrón de 
expresión. Esto es, altos niveles de RAB7 correlacionan con alta tasa proliferativa 
celular, mientras que una reducción de la expresión de RAB7 se asocia con un 
incremento en la capacidad metastásica. Esto se debe a que la maquinaria de 
degradación lisosomal desvía las vesículas hacia un proceso secretor, donde 
curiosamente otra de las proteínas de la familia de las RABs tiene un papel 
perfectamente descrito RAB27. Precisamente RAB27 es comúnmente aceptado 
como un efector de factor de transcripción MITF, uno de los oncogenes de linaje 
celular específicos en melanoma más ampliamente estudiados. 
 
Por todo eso, esta tesis doctoral se fundamenta en el estudio de (1) las diferencias 
en tráfico vesicular regulado tanto por RAB7 como por RAB27 en melanoma. (2) 
Análisis proteómico global de los cambios en el proteoma inducidos por el 
silenciamiento de RAB7 o RAB27 en el interior celular o en la fracción secretada. 
(3) Caracterización de las diferencias en la capacidad invasiva y metástasica 
controladas por RAB7 o RAB27. En el transcurso de esta tesis se han definido las 
diferencias de forma autocrina y paracrina en cuanto al potencial invasivo celular, 
siempre fundamentándose en la expresión de RAB7 y RAB27 como objeto de 
estudio. Además, tras la depleción de RAB7 o de RAB27 se han llevado a cabo 
experimentos de análisis proteómico masivo partiendo tanto de extractos 
II. Summary/Presentación 
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celulares como de medio celular condicionado, y su análisis han permitido la 
identificación de una novedosa vía de señalización metabólica esfingolipídica. Este 
reciente hallazgo es debido a la dependencia de RAB7 en la producción de 
caramida. Por otro lado, el análisis del secretoma celular nos ha permitido 
identificar nuevamente un grupo de genes implicados en el tráfico lisosomal 
específicamente secretado; dentro del cual encontramos LRP2, una proteína de 
transmembrana. En un estudio más detallado en referencia a RAB7 y LRP2 se ha 
establecido un inesperado efecto prometastásico, donde LRP2 se presenta como 
un efector de RAB7 específicamente localizado en dominios enriquecidos en 
ceramida de vesículas que son posteriormente secretadas.. A la luz de estos 
resultados, se establece que esta tesis doctoral profundiza en el conocimiento del 
tráfico vesicular en melanoma, y además revela una novedosa intercomunicación 
mediada por la modulación del tráfico vesicular y el metabolismo esfingolipídico 
en el melanoma cutáneo 
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1. Melanoma:  A XXI century global challenge 
 
Cutaneous melanoma is a malignancy that arises from the transformation of the 
pigment-producing cells that reside on the skin called melanocytes1. Although it 
accounts for less than 3%  of skin cancer cases2, it  is responsible for approximately 90% 
of skin cancer related deaths3.  
 
Even though the overall cancer incidence has declined worldwide in the last decades4, 
this is not the case for melanoma.  The number of new cases of this disease has constantly 
increased during the last 30 years 2,4 .  In 2017, more than 74000 new cases of cutaneous 
melanoma were diagnosed in USA4.  Numbers almost doubled compared to the 40000 
cases diagnosed in 20125. This tumor is also the 5th and the 6th most common cancer type 
in males and females, respectively4 (Figure 1). Curiously, incidence rates are 60% 
higher in men than in women, while death rates are more than double4. Several studies 
have shown that sex is an independent predictor of survival6,7 , although the ultimate 
cause of this difference is not clear. 
 
 
 
 
 
 
 
 
 
 
 
One of the main features of cutaneous melanoma is its intrinsic capacity to metastasize 
8,9 and high resistance to traditional chemotherapy10.  One reason  is because melanoma 
is the solid tumor with the most complex (epi)genetic background, with over 80,000 
Figure 1: Ten Leading Cancer Types for the Estimated New Cancer Cases by Sex, USA, 2017. 
Adapted from Ref 4. 
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mutations11.  This high mutational load has been a hurdle for the rational design of 
therapies against it. Until recently, apart  from surgical resection at early stages, no 
therapeutic  approach has been shown to be effective in increasing patient survival12.  
However, in the last years our knowledge about this disease has improved dramatically 
leading to important scientific milestones13 that have increased the 5-year overall 
survival of metastatic melanoma patients to 50%14. However, the past decade have 
witnessed critical scientific achievements/milestones that ultimately have led to the 
increase of the survival rates. 
 
Nevertheless, despite all the progress in the last years, there is still an unmet need of 
achieving a better understanding of melanoma biology and the mechanisms this tumor 
exploits to metastasize in order to find new biomarkers and targets for melanoma 
treatment. 
 
 
2. Melanocyte:  The starting point 
 
Melanocytes are dendritic cells that migrate from the neural crest to the skin during 
embryogenesis1. Specifically, they reside in the basal layer of the epidermis and in the 
hair folicules15.  There, melanocytes establish contact with surrounding keratinocytes, 
typically in a ratio 1:101,16, giving rise to the so-called epidermal-melanin unit17. This 
structure is essential for cutaneous melanocytes function, which, briefly, is to provide 
melanin pigment to their neighbor keratinocytes18 by the means of specialized 
membrane vesicles termed melanosomes19. Melanosomes are a type of Lysosome-
related-organelles (LROs) specific from pigmented cells, such as melanocytes and 
melanoma, that accumulate melanin pigments20. Upon UV light stimulation, 
keratinocytes produce Melanocyte-Stimulating Hormone (MSH) which  leads to the 
induction of Microphtalmia-associated Transcription Factor (MITF) to promote melanin 
synthesis21. Melanin provides hair and skin pigmentation, photoprotection and 
thermoregulation18,22,23.   
 
Unlike keratinocytes, melanocytes divide very unfrequently (less than twice a year)24. 
Thus, genomic alterations in these cells accumulate during very long periods and give 
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rise to both benign and malignant proliferative and pigmentation disorders. (They will 
be discussed in the next section). 
 
 In addition to the skin, melanocytes also migrate to other organ sites such as  eyes25 and, 
to a lesser extent, heart26,  ears27, leptomeninges28 and oral and genital mucosal 
membranes29. Depending on the place of origin, their malignant transformation gives 
rise to distinct types of melanocytic neoplasms, with different etiological and 
histopathological characteristics30,31.  
 
 
3. Classification of melanocytic lesions: Benign Neoplasms 
 
Benign neoplasms of melanocytic lineage are termed nevi. Nevi are proliferations of 
melanocytes originated by gain of function mutations in oncogenes, which show a 
mutually exclusive pattern31 (Table 1). However, nevi do not generally progress to 
melanoma due to the mechanism of 
Oncogene Induced Senescence32. 
 
Multiple type of nevi have been described. 
Among them, the most abundant are the 
Common Acquired Nevi, which are 
approximately 2mm in diameter. 
Caucasian individuals have between 20-
30 of these nevi.33,34 Congenital Nevi are 
those acquired shortly after or present at birth35. These two type of nevi can be stratified 
into junctional dermal, compound or dysplastic nevi  according to their growth pattern, 
and specific location within the skin36. Of particular interest is the case of patients with 
dysplastic nevi, since they appear to have higher risk of developing melanoma37–39.  
However, whether dysplastic nevi are benign lesions or melanoma precursor is a long-
standing debate 38,40. Other less frequent benign nevi are Spitz nevi and Blue nevi41,42. 
 
Currently there is extensive research in nevi diagnose and classification43,44. Because 
some mutations observed in nevi  are also frequently observed in melanomas45–47 and 
Table 1: Most Common Nevi Subtypes and their 
most frequently associated mutated oncogene. 
Adapted from Ref36,39,42,45 
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are histologically similar to them48. this resemblance may lead to misdiagnose and 
medical malpractice49. 
 
 
4. Malignant Neoplasms: Melanoma 
 
Melanomas have been classified following several criteria such as: anatomical location, 
histopathological type and sun exposure level41. Wallace Clark50 developed a proposal 
four decades ago, in which cutaneous melanoma can be subdivided into several 
categories: superficial spreading melanoma (SSM)51, lentigo malignant melanoma 
(LMN)52,  nodular melanoma (NM)51 and acral lentiginous melanoma (ALM)53. However, 
it is becoming clear that cutaneous melanomas should be sub classified attending to their 
genetic profile rather than any other classification54.  
 
Melanocytes from non-cutaneous tissues can also give rise to rare forms of melanoma, 
such as uveal melanoma and mucosal melanoma in the eye and genitourinary track, 
respectively.  These melanomas are genetically very different to the cutaneous ones55 
and have different impact in patient prognosis and survival30,56. 
 
3.1 Clark model of stepwise-progression 
 
The traditional multi-step model of melanoma progression involves a linear model of 
evolution from melanocytes to primary melanoma based in histological criteria57,5858. 
Five different steps were proposed attending to the lesion depth of invasion. 
 
Melanocytic Nevi:  It refers to the proliferation of common melanocytes.  These 
melanocytes stop proliferating due to mechanisms of oncogene-induce-senescence 
(OIS)32 and more than 80% of them have mutations in BRAF gene45. 
 
Dysplastic Nevi: This phase is characterized by aberrant growth of melanocytic 
nests, which can arise from a preexisting  nevus  or as a novel lesion54. 
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Radial Growth Phase (RGP): Horizontal proliferation of melanoma cells, 
generally confined into the epidermis. They have to overpass the OIS barrier by 
acquiring novel mutations that lead to active proliferation but not invasive capacity 
yet57,59. The most frequent genetic alterations are: CDKN2A60, PTEN61 and NF162. 
 
Vertical Growth Phase (VPG): In this phase, the tumor starts growing vertically 
to invade the dermis. VGP melanoma cells have increased motility and interact with the 
surrounding stroma to promote metastasis63,64 and generate an immunosuppressive 
environment65. Several transcriptomic analysis have unveiled that the transition from 
RGP to VGP has the highest level of molecular changes66,67. Important alterations in this 
phase are mutations in the MAPK pathway, as well as TERT and SWI/SNF chromatin-
remodeling complex38. 
 
Metastatic Melanoma: this phase occurs when melanoma cells have 
disseminated through the body and colonized distant organs57. Cutaneous melanoma 
metastasizes more frequently to the lymph nodes  first68,69 and later , to distal organs 
such as brain, liver, bones and lungs70,71, while uveal melanoma metastasis occurs almost 
always in the liver72. This difference in tropism has opened a new lines of research 
focused on how tumor cells from the primary tumor can secrete soluble and vesicle-
associated proteins that  prepare the premetastatic niche73–75. 
 
Although the Clark model of melanoma progression has been the gold rule for melanoma 
clasification76, its application has been hampered by the fact that only 20-30% of the 
melanomas follow a linear progression77: Up to 80% of cutaneous melanomas and all of 
mucosal melanomas lack the histopathological features of pre-existing nevus31,78–81. 
Therefore, this tumors may rise from primary melanocytes or precursor cells70, although 
the exact contribution of melanocytes or stem cell precursors to melanomagenesis is 
controversial.82,83. Moreover, lesion thickness is very prone to measurement error, 
sentinel lymph node excision has not showed a beneficial for  patient survival84,85  and 
there are no clear molecular markers to distinguished between the different categories. 
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3.2 Nonlinear progression: Genetic classification 
 
In an attempt to unravel melanoma complexity, several genomic studies using parallel 
sequencing over hundreds of melanoma cases from different stages have shed light 
about the most prevalent oncogenes and have helped to define patient subgroups55,86,87. 
One of  the most extensive studies was performed by The Cancer Genome Atlas (TCGA)87, 
which characterized 333 cutaneous melanomas at DNA, RNA and protein level to 
establish a genomic/transcriptomic framework of melanoma classification with 
potential biological and clinical significance. 
 
Cutaneous Melanoma TCGA Consortium revealed four main subgroups of patients 
attending to the prevalence of the most predominant mutated genes (Figure 2):  
 
1. BRAF mutant: 52% of patients harbored BRAF somatic mutations and of those, the 
most frequent was V600E, followed by V600K and V600R mutations. This subtype is 
also characterized by MITF amplifications and is more frequent in younger patients.  
Figure 2: Landscape of driver mutations in TCGA-melanoma. Total number of mutations, age at melanoma 
accession, and mutation subtypes are indicated for each sample. Color-coded matrix of individual mutations 
(specific BRAF and NRAS mutations indicated) (middle), type of melanoma specimen (primary or metastasis), 
and mutation spectra for all samples (bottom) are indicated. Adapted from Ref87 
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2. RAS mutant: Hot-spot mutations in any of the three RAS family members (N,H, K, 
and H) give rise to the second largest subset of patients, 28% of patients. Of those, 
the immense majority harbor NRAS somatic mutations, the most abundant are Q61R 
and Q61L. This subtype also has increased MAPK activity and AKT3 overexpression. 
 
3. NF1:  About 14% of melanoma patients show loss of function of the NF1 gene, which 
results in a non-canonical activation of the MAPK pathway. These patients have 
higher mutational burden and they tend to be older than average.  
 
4. Triple Negative:  This is a heterogeneous group of patients characterized by a lack 
of alterations in the above-mentioned genes. They also have higher genomic 
rearrangements. 
 
3.3 Cutaneous vs Non-Cutaneous Melanomas 
 
Acral and mucosal melanomas have different histological and genetic characteristics to 
cutaneous melanoma. These two melanoma subtypes are more common in non-
Caucasian populations88–90 and are frequently localized in the body cavities (mucosal 
melanoma) and palms soil and nails (acral melanoma)31. Unlike cutaneous melanoma, 
acral and mucosal melanomas have lower somatic mutation burden but  higher large-
scale genomic rearrangements55,91,92.   
 
 
5. Melanoma dependency: “Oncogenic” Vs “Non-Oncogenic” Addiction. 
 
As melanoma is the solid tumor with the highest rate of somatic mutations11, one of the 
most challenging areas of research has been the identification of tumor dependencies 
such as genes and pathways that can be exploited for cancer therapy. 
 
Multiple melanoma oncogenes have been identified so far87, and some of them have been 
exploited for targeted therapy, which paved the way for personalized medicine13. 
However, it is becoming increasingly accepted that tumor cells hijack multiple cellular 
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programs to allow them to survive in deleterious circustances93. Although these 
pathways are not intrinsically oncogenic themselves, they may  be exploited 
therapeutically93. 
 
4.1 Melanoma Oncogenic Dependencies:  Classical vs Lineage-Specific 
 
The majority of oncogenes involved in melanoma development have impact on MAPK 
and PI3K pathways, as well as cell cycle checkpoints (Table 2).  These factors are termed 
“classical oncogenes”94 since they are shared by many tumor types95. 
 
However, there are also some genes, which are activated in a lineage-specific manner, 
i.e. they are unique to a particular tumor type. In melanoma, the best characterized 
lineage-specific oncogene is MITF96. By promoting the transcription of several genes 
involved in proliferation (CDK2), pigmentation (TYR, TYRP1, TRP2 or RAB2797,98) and 
survival (BCL2A1, BCL2 and BIRC799,100) it is considered the master regulator of 
melanocytic development and function. Around 20% of melanoma patients  show MITF 
amplification96. Similarly pro-oncogenic functions have been identified or proposed for 
some genes regulated by MITF such as: RAB27101 and BCL2A199. But surprisingly, 
primary tumors and melanoma cells  with low or none MITF levels are highly invasive 
and metastatic102–104.  This contradiction led to the proposal of the rheostat model, in 
which MITF-low cells are more stem cell like and invasive, whereas MITF-high cells are 
more proliferative105.  
 
Importantly, our group has recently identified several lineage-specific genes involved in 
mechanisms of regulation in melanoma, both acting in an MITF-independent manner, 
such as RAB7104and CUGBP1106, or directly regulating MITF levels/activity, as is the case 
of CPEB4, which  regulates MITF post-transcription modifications107. 
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Table 2: Melanoma Oncogenes and Tumor Suppressors.  a: 10% acral and mucosal; b: 70-80% uveal; 
c: metastatic.  Adapted from Ref22,95,108–110 
 
 
 
4.2 Melanoma Non-Oncogenic Dependencies 
 
In addition to the aforementioned role of oncogenes in melanoma, tumors might have 
“non-oncogenic addictions”, which are pathways non-intrinsically oncogenic per se, but 
that can act as facilitators of the tumorigenic process93. Our laboratory recently 
identified a novel non-oncogenic dependency of melanoma involving the lineage specific 
wiring of the vesicular trafficking machinery to foster tumor progression and metastasis 
104.  
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6. Vesicular Trafficking: A novel Melanoma Non-Oncogenic Dependency  
 
Autophagy, together with endocytosis and exocytosis are the three main vesicle-
mediated pathways involved in the intracellular transport of proteins across the cell 
cytoplasm. In the tumoral microenvironment, cancer cells are anchored to the 
extracellular matrix and surrounding cells by transmembrane proteins. Some of this cell 
surface proteins might also function as receptors, and once engaged by their ligand in 
order to trigger downstream signaling they are endocytosed and targeted for lysosomal 
degradation 111–115. Additionally, by exocytosis, cells also secrete macromolecules to 
influence behavior of the surrounding environment in order to make it more 
supportive116. Finally, in order to maintain cell homeostasis, damaged organelles and 
proteins are degraded by a process termed Autophagy (Figure 3).  A fine tuning of the 
intracellular trafficking is so important that alterations in the sorting of growth factor 
receptors, unbalanced recycling of integrins, dissolution of cell-cell junctions and 
abnormal secretion has emerged as a multifaceted hallmark of cancer117–119.  
 
5.1 The Troika: Endocytosis, Exocytosis and Autophagy 
 
Endocytic pathways comprise the uptake of material from the extracellular space and its 
retrograde transport to the lysosomes120. This process begins with the inward budding 
of vesicles from the plasma membrane that progress to form endosomes, which move 
from the cell periphery towards the perinuclear region. The molecular actors involved 
in endosome maturation change during the transport: Early endosomes are positive for 
the small GTPase RAB5111,121and EEA1122,123,  among others, but during maturation these 
trafficking regulators are substituted by new ones such as RAB7120,124,125 RILP126  and 
VPS34127, which are late endosomal markers. Finally, these vesicles fuse with lysosomes, 
which are the major degradation site of eukaryotic cells. Cargo is subsequently degraded 
by acidic enzymes104,116,128–130 contained in these organelles and  used to generate ATP 
or  utilized for biosynthetic pathways. Lysosomes are the end-point of both, the 
endolysosomal pathway and autophagy (Figure 3)                                                                                                                                                                                                      
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Figure 3: Schematic representation of  vesicular trafficking pathways inside a cell.  Endocytosis (green) 
exocytosis (orange) and autophagy (red). Note the central roles of RAB7 for endocytic and autophagy pathways 
and RAB27 role in exocytosis 
 
 
Exocytosis is the reverse mechanism to endocytosis. It involves the anterograde 
transport of intracellular vesicles or newly synthesized extracellular proteins outside 
the cell in order to exert “extra-cellular signalling”118,119,131–133. As in the case of 
endocytosis, there are several mechanisms of secretion: The recycling of endocytic 
material back to the plasma membrane133,134, constitutive secretion of newly 
synthesized proteins from the Trans Golgi Network (TGN)135,136 and exovesicle 
secretion118,137 (Figure 3). The secretome englobes all soluble proteins or exovesicles 
secreted by cancer cells. Cancer derived secretome is emerging as a critical player in 
cancer metastasis, particularly in the preparation of premetastatic niches75,138, in which 
melanoma is no exception71,74. 
 
Autophagy is a regulated catabolic process that consists in the degradation of 
cytoplasmic material within doubled-layered vesicles (autophagosomes) that fuse with 
the lysosomes (Figure 3). It is a dynamic recycling system essential for cell homeostasis 
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by regulating organelle and protein turnover139. Depending on the context140, 
autophagy  may have a tumor promoter141,142 or anti-tumoral activity143–145. However, 
in the case of melanoma, autophagy has been proposed as an “Achilles’ heel”146–148since 
this tumor type employs autophagy for growth and survival149. Inhibition of basal 
autophagy, or several components of the pathway143,150, as well as lysosomal biogenesis, 
compromises melanoma viability104,143. 
 
5.2 Lipids, the invisible player 
 
Metabolic reprogramming is a well stablished hallmark of cancer117. One of the pathways 
that is becoming well recognized as supportive of tumor growth and metastatic 
dissemination is lipid metabolism151,152. Highly proliferative tumors need to satisfy their 
lipids requirements for several biochemical purposes. For a long time lipids have been 
regarded as mere components of the plasma membrane and vesicles with only structural 
roles.  However, some species of lipids such cholesterol and ceramide have been 
described to also play a role in several steps of vesicle formation, trafficking and 
secretion153–157. Nevertheless, more in‐depth analyses of the role of lipids in vesicular 
trafficking to drive melanoma progression and metastasis needs to be performed. 
 
5.3 Rab Proteins: the organizers 
 
These three pathways are  finely regulated by the (Ras-like-Rat-Brain) RAB proteins, the 
largest family of small GTPases133. Each Rab protein regulate a  particular step of 
vesicular trafficking and control each of the four major steps in membrane traffic 
(namely vesicle budding, delivery, tethering, and fusion)133by assembling multiprotein 
machinery in the cytoplasmic surface of intracellular membranes.  They have a cyclical 
mechanism of activation and inactivation depending on GTP  or GDP binding. This switch 
is controlled by guanine nucleotide exchange factors (GEFs), which trigger GDP 
dissociation and GTP binding, and GTPase‐activating proteins (GAPs), which accelerate 
hydrolysis of the bound GTP to GDP. After translation, RAB proteins also undergo a 
prenylation process by Rab geranylgeranyl transferase (RabGGT) in order to be 
anchored to vesicles membranes158–160.   
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7. RAB7: Master regulator of vesicular trafficking 
 
We have reported a cluster of lysosome‐associated genes that distinguishes melanoma 
from over 35 different tumor types and among this cluster of genes, we identified the 
small GTPase RAB7 as the master controller of this gene set (Figure 4). 
 
 
Figure 4: Melanoma Enriched Lysosomal Cluster. GSEA heat map showing a selective enrichment of the 
Lysosome Gene Ontology cluster ( GO:0005764). RAB7 is highlighted. Adpated from Ref104 
 
 
This small GTPase is one of the most characterized RAB proteins. It governs early-to-
late endosomal maturation and late endosomes fusion with lysosomes124.  Nevertheless, 
RAB7 has been shown to play a roles in several  physiological processes161: 
 
RAB7 
N=55 N=850 
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6.1 Role in Endocytosis 
 
RAB7 is usually present on late endosomes after the generation of RAB7-domains162,163 
generated after the loss of RAB5, (early endosomal marker) in a  highly coordinated 
switch 162,164. Genetic loss of rab7 results in embryonic lethality around E7-8 due to 
alterations in the endocytic compartiments165.   The endocytic pathway begins with the 
initial recruitment of RAB5 to early-sorted endosomes. This process is mediated by 
Rabex-5166,167, a RAB-GEF whose activity is promoted by the RAB5 effector Rabaptin-
5168.  These three proteins form a complex in the early endosomes membrane that 
triggers a positive feedback loop stimulating the  rapid recruitment of RAB5 effectors to 
RAB5-positive organelles169,170. RAB7 replaces RAB5 when the feedback loop is 
inhibited or a RAB-GAP stimulate RAB5-GTP hydrolysis. SAND-1/Mon1 and Ccz1 play a 
key role in the RAB5 to RAB7 switch. SAND-1/Mon1 displace Rabex-5 to interrupt the 
positive feedback loop164 and recruit and activate RAB7 by engaging  RAB7 GEF on the 
Mon1-Ccz1 Complex 171,172. Then, RAB7 is activated by this complex in the late 
endosomes membrane and dissociates once lysosome-late endosome fusion has 
ocurred173. Interestingly, it was recently reported that  dephosphorylation of RAB7 by 
PTEN inhibits the complex RAB7 Mon1-Ccz1 and blocks its translocation to late 
endosomes174. 
 
 Together with the RAB5-RAB7 switch, there are changes in the protein machinery 
that allow endosomes to recognize and fuse with other endosomes and lysosomes. The 
Homotypic fusion and Protein Sorting (HOPS) complex replaces the Class C CORe 
Vacuole/Endosome Tethering (CORVET) complex175,176. These two complexes play an 
essential role in the tethering and fusion machinery for early and late endosomes 
respectively. However, the mechanism of action of HOPS in mammalian cells  is not fully 
understood as it differs from yeast177–180. The small GTPase Arl8b, but not RAB7 is 
essential for the assembly of the HOPS machinery and the recruitment of Vps41 to the 
lysosomal mebrane180. In addition an effector of RAB7, RILP, is able to recruit HOPS in 
a  RAB7 independent manner179 and by binding to ORP1L and the dynein motors allow 
the retrograde transport  and fusion of late endosomes with lysosomes178,181.  There are 
currently three proposed models: (1) Maturation of late endosomes to lysosomes(2) 
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“Kiss and run” model, continuous fusion and fission events between late endosomes and 
lysosomes and  (3) direct fusion of both organelles to create a hybrid one termed 
endolysosome182,183.    
 
 However, which steps of the endocytic pathway are specifically regulated by 
RAB7?  This question has been addressed by using loss-of-function experimental 
models, particularly  dominant negative mutant (DN) of RAB7. In the presence of DN-
RAB7, VSVG protein184,  CTSD and CI-M6PR185 are trapped in early endocytic 
compartments, suggesting that RAB7 mediates the transport of early to late endosomes. 
But RAB7also exerts functions downstream late endosomes/Multivesicular Bodies 
(MVB)  since RAB7-DN decrease the degradation rate of EGF.EGFR complex  in the 
lysosomes and induces accumulation of late endosomes186,187. Furthermore, RAB7 also 
plays a role in lysosomal biogenesis by regulating the retromer transport of newly 
synthetized cathepsins from the Golgi apparatus to the lysosomes188–190. RAB7-DN 
expression causes missorting of the acid hydrolases191, dispersal of the perinuclear late 
endosomal and lysosomal compartment, and block cargo trafficking to 
lysosomes104,124,192. Also lysosomal acidification is severely perturbed, therefore 
affecting at the well-functioning of acid hydrolases193–195. Actually RAB7 regulates 
activity of the vacuolar ATPase through RILP interaction196–198 but optimal pH also 
depends on lysosomal positioning in the cytoplasm198. On the other side, expression of a 
constitutively active mutant causes formation of large endocytic structures in the 
perinuclear region, and accelerates EGF lysosomal degradation104,124,186.  
 
6.2 Autophagy 
 
Rab7 plays a key role in macroautophagy (hereafter autophagy) specifically in the final 
step, which leads to autophagosome maturation. In fact, autophagosomes fuse initially 
with early endosomes to form amphysomes, a “hybrid” organelle that lack lysosomal 
hydrolases but is able to fuse with late endosomes also199,200. As in the case of 
endosomes, during maturation, autophagosomes move towards the perinuclear region 
while undergoing pH acidification. RAB7 regulates this movement by the action of 
RILP120,125,201. The role of RAB7 in autophagy has been addressed in several cellular 
models. In cardiomyocytes ALDH2 activation induces RAB7 upregulation and increase 
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of the autophagic flux, with important implications in cardioprotection202. On the 
contrary, although RAB7 silencing or DN mutants do not affect early stages of 
autophagosome maturation120,125 it does affect late stages of maturation:  Actually 
increasing RAB7 labeling intensity and colocalization with LC3 was observed during 
vacuole maturation. However, RAB7 positive autophagosomes were detected before 
they acquire LBPA or LAMP1 staining104,120,125.  Finally  RAB7 was also shown to mediate 
the fusion of late autophagosomes with lysosomes: In cardiomyocites, ablation of the 
COP9S signalosome lead to an extensive accumulation of autophagosomes and 
downregulation of RAB7 levels203. In addition, after starvation, or mTOR inhibition RAB7 
depletion leads to blockage of late endosomes and autophagosomes with lysosomes to 
accumulation of late autophagosomes. Similar to what occur upon treatments with drugs 
that block lysosomal fusion104,120,204. However, upon prolonged starvation, there is an 
mTOR reactivation needed to restore lysosomal homeostasis, process termed 
Autophagic Lysosome Reformation (ALR). RAB7 is located only in lysosomal fractions, 
and it must dissociate from the lysosomal membrane for ALR to occur.  Expression of a 
constitutively active  RAB7 mutant abrogates ALR resulting in enlarged 
autolysosomes205. Also,   Rapamycin treatment inhibit ALR and blocks RAB7 dissociation 
from autolysosomes, suggesting RAB7 acting downstream mTOR to regulate ALR205–207.  
All this results reinforce the role for RAB7 in final maturation and fusion of late 
autophagic vesicles. 
 
By interacting with different effectors, RAB7 also plays a role in a different type of 
autophagy: Mitophagy, which is the selective degradation of mitochondrias by 
autophagy.  PINK1 and Parkin are they key controllers of this process.  RAB7 together 
with TBC1D15/TBC1D17 (RAB-GAPs) and FIs1 are downstream effectors of Parkin. 
TBC1D15 binds to LC3 and Fis1 to coordinate RAB7 activity208 RAB7-GTP forms and 
stabilizes mitochondrial-lysosomal contacts sites, while upon TBC1D15 mediated 
hydrolysis of RAB7-GTP,  these contacts are no longer maintained209. RAB7 silencing in 
TBC1D15 KO cells prevent the accumulation of LC3 positive vesicles210,211.   
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6.3 Cytoskeleton 
 
RAB7 can regulate anterograde vesicle transport mediated by kinesin motors211 and 
retrograde movement of organelles along microtubules181.  However, it can also regulate 
the formation of intermediate filaments and actin cytoskeleton. 
 
In RAB7 silenced cells, there is an increase in the amount of insoluble peripherin and 
vimentin  (Intermediate Filaments components), while expression of the constitutively 
active RAB7 protein has the reverse effect212,213 .  
 
Actin cytoskeleton is in partly regulated by Rac1 small GTPase. It was recently described 
how RAB7 interacts with Rac1  by the action of Armus214,215. RAB7 overexpression 
increased Rac1 activity while RAB7 inactivation caused Rac1 inactivation216. 
Furthermore RAB7 overexpression induces the formation of circular dorsal ruffles, 
membrane protrusions enriched in actin filaments216. 
 
6.4 RAB7 in specialized cells 
 
RAB7 controls late endosome and autophagosome fusion with lysosomes. However, it 
may play another role in particular cell types. 
 
Osteoblast are a type of bone cells important for the degradation of bone matrix. In this 
cells RAB7 is mainly localized in the ruffle border of the plasma membrane217, where It 
mediates secretion of lysosomal enzymes to the extracellular space important for the 
bone matrix degradation.  
  
RAB7 is especially important in the immune system cells218,219 as it also plays a critical 
role during phagocytosis. This is the process of internalization of  particulate matter to 
phagosomes, and RAB7 mediates the fusion of phagosomes with late endosomes and 
lysosomes126,220 in a similar manner as described above. Actually, some pathogenous 
microorganisms are able to bypass this cell defense mechanism by hijacking RAB7 or 
RAB7 interactors after being phagocytosed, blocking phagosomal maturation and 
acidification221–223.  
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In neural cell cultures, RAB7 interacts with the Tropomyosin receptor kinase A (TrkA)224 
and a recently identified RAB7-effector, Protruding225,226,  to drive neurite and 
protrusion outgrowth. RAB7 coordinates with RAB5 to regulate retrograde axonal 
transport, RAB7  impairment induces a complete blockage in axonal transport227. Finally, 
together with other RABs, RAB7 regulates neural migration and dendritic 
morphology228.  Hereditary heterozygous mutations  in RAB7 are responsible of  a 
peripheral neuropathy disease called Charcot-Marie-Tooth type 2B (CMT2B)229,230. The 
fact that mutations in RAB7 only cause neural symptoms even though RAB7 is 
ubiquitously  expressed in all tissues might be explained by a neuronal specific function 
of RAB7.  
 
Focusing in melanoma, RAB7 has been shown to play a role in melanosome biogenesis  
by directing TYRP1 protein to  Type I melanosomes231 and early melanosome motility232.  
Pigmentation-related pathways are of special importance in melanoma, since they are 
usually exploited  by the tumor to foster progression: Melanosomes derived from early 
melanomas have been shown to influence the formation of tumor microenvironment63. 
Additionally, TYRP1 mRNA is able to sequester miR-16 to direct a specific gene 
expression program that favors melanoma growth233. These findings reinforce the idea 
of non-oncogenic addiction of tumors by hijacking a non-tumorigenic cellular program.  
 
6.5  Oncogene or Tumor Suppressor? 
 
The specific role of RAB7 in cancer is controversial, with several reports supporting its 
oncogenic role 104,234,235, while others state it is a tumor suppressor236–239. 
 
RAB7  was found necessary to maintain prosurvival signaling in cancer cells234. 
Furthermore, invasion and migration were found to be inhibited by RAB7 inactivation 
in HeLa and HT-1080 fibrosarcoma cells235, but favored in prostate cancer cell 
lines237,239, also, in fibroblasts, RAB7 silencing induces survival upon growth factor 
withdrawal by blocking lysosomal degradation of glucose transporters236.  Actually, 
upon starvation RAB7 is activated on lysosomal membranes triggering apoptosis240. 
Also, dominant-negative Rab7 cooperated with E1A to promote the transformation of 
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p53(-/-) mouse embryonic fibroblasts (MEFs)236.  Regarding the role of RAB7 in the 
microenvironment, Endothelial cells (ECs) from a lysosomal acid lipase KO mice, 
facilitate melanoma growth and metastasis and display higher RAB7 levels RAB7 
inhibition revers the tumor supportive role of the ECs241.   
 
However, our group recently identify RAB7 as the master regulator of a cluster of 
lysosomal proteins that differentiate melanoma from other 35 tumor types (figure 4). 
Further characterization studies showed that RAB7 levels were modulated during tumor 
progression, being induced at early stage, but undergoing partially downregulation in 
invading melanomas (figure 5A). Actually, lower RAB7 levels was a predictor of poor 
prognosis (figure 5B) 104.   
 
Figure 5: RAB7 expression in human biopsies and Prognostic value: A Confocal immunofluorescence (IF)-
based quantification of the mean RAB7 protein expression per melanoma cell in a representative whole-tissue 
VGP melanoma specimen. Blue color represents stromal cells. B Kaplan-Meier curves showing 10-years 
metastasis-free survival upon resection of primary melanomas. Patients stratified in function of high and low 
protein levels in primary tumor specimens. Adapted from Ref104 
 
 
Functional analyses showed that when RAB7 levels were diminished in melanoma cell 
lines, they became more metastatic  due to changes in the cytoskeleton, translocation of 
lysosomal hydrolases to the plasma membrane and modulation of gene expression 
profiles104. We also demonstrated the pro-oncogenic role of RAB7 in melanoma 
initiation by showing the requirement of RAB7 to delay PI3K driven OIS in primary 
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melanocytes242, supporting the non-equivalent role of RAB7 in melanoma compared to 
other systems.  
 
Nevertheless, the mechanism behind RAB7-dependent increased metastasis, and 
relation with other mechanism of vesicular trafficking is not fully understood. 
 
8. RAB27 a new player downstream RAB7? 
 
RAB7 is not the only RAB protein that has been characterized in melanoma.  The small 
GTPase RAB27a (hereafter referred as RAB27) was previously identified  as a melanoma 
driver  by bioinformatics approach101. RAB27 is an MITF97 effector and CPEB4107 target, 
two melanoma lineage-specific factors.  
 
RAB27 was the first RAB protein identified whose mutations were linked to a disease. 
Type 2 Griscelli syndrome is a hereditary disease characterized by partial albinism and 
immunodeficiency caused by mutations in the RAB27 gene. RAB27 is involved in 
exovesicle secretion232,243. Thus, mutations in this gene make the protein unable to bind 
and secrete melanosomes, causing pigmentary dilution244,245 and affects  the exocytic 
capacity of several cell types such as lytic granule secretion of NK cells and CD8+ T 
cells245 producing immunodeficiency. 
 
7.1 RAB27 role in specialized cell types 
 
RAB27 is highly expressed in secretory cell types, especially in melanocytes, immune 
system and pancreatic beta-cells.  In melanocytes, RAB27, together with its adaptor 
proteins Myosin Va and Slac2-a, regulates the anterograde transport of melanosomes in 
F-actin filaments to the plasma membrane232,246,247, where Slac2-a is replaced by Slp2 to 
allow membrane docking of melanosomes248. The RAB27-mediated secretory 
mechanism is not as well understood in other secretory cells, mainly because many 
RAB27 effectors are simultaneously present on secretory granules and they might be 
tissue specific as well249,250. 
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Although RAB interactors are known to bind to RAB proteins when they are GTP-bound, 
in the case of RAB27, Coronin-3 was identified as a RAB27-GDP bound effector that 
controls endocytosis of pancreatic-beta cells251.  
 
7.2 Role in cancer 
 
Deregulation of RAB27  expression has been reported in several tumor types, acting as 
an oncogene in pancreatic cancer252, hepatocellular carcinoma253, glioma254, breast 
cancer255, bladder cancer256 and melanoma74. However, RAB27 is often downregulated 
in advanced prostate cancer257 and colorectal cancer258. 
  
RAB27 plays a role in several tumor types by regulating exosome secretion. Exosomes 
derived from cancer cell lines have been shown to prepare the niche for distal 
metastasis74,75, participate in the establishment of a tumor-promoting  
microenvironment and increase resistance to therapeutic agents259.  In melanoma74 
breast260  and kidney cancer261 cell lines, RAB27 depletion abrogates exosome secretion 
and decreases tumor progression and metastasis.  
 
It was recently reported that the role of RAB27 in cancer progression might not be only 
limited to exosome secretion as it was found to be involved in glutamate-driven 
recycling of  MTP1-MMP-containing vesicles back to the plasma membrane262 and might 
regulate NF-KB signaling to promote tumor growth256. 
 
In the case of melanoma, RAB27 levels increase during melanoma progression, unlike 
RAB7, which behaves as a rheostat favoring either proliferation or invasion (figure 6). 
Whether RAB27 plays a role in RAB7-mediated increase in metastasis104 is unknown. 
Therefore, this PhD thesis will focus in expanding the knowledge of vesicle trafficking 
machinery in melanoma pathogenesis in the context of RAB7 and RAB27. 
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Figure 6: Model of expression levels and functions of RAB7 and RAB27 in melanoma progression. 
RAB7 has an oscillating pattern of expression during tumor development while RAB27 has an increased 
expression during melanoma progression.  
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Melanoma is a paradigm of histopathologically complex tumors, proceeding with 
the highest mutational rate known to date. Our laboratory has shed light on how 
melanoma cells exploit a lineage‐specific wiring of the endolysomal pathway to 
sustain and acquire cancer hallmarks.  We identified a cluster of Lysosomal genes 
differentially upregulated in melanoma. Of those genes, RAB7 plays a key role in 
favoring melanoma growth and metastasis. However, whether there is a cross-talk 
between RAB7 and other vesicular trafficking modulators such as RAB27, both 
melanoma lineage specific oncogenes, and the mechanism of RAB7-dependant 
increase in metastatic potential is still unknown. Therefore, the Specific Aims of 
this PhD thesis study are as follows: 
 
1. To analyze cytoplasmic alterations and cellular fitness induced by 
depletion of vesicular trafficking modulators RAB7 and RAB27 
2. To perform a global proteomic analysis of intracellular and secreted 
fractions of melanoma cell lines upon RAB7 and RAB27 depletion  
3. To define the functional differences between RAB7 and RAB27 increase in 
melanoma metastasis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 43 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
MATERIALES Y MÉTODOS 
 
 
 
 
 
 
V. 
V. Materials and Methods/ Materiales y Métodos 
45 
 
 
1. Cell culture 
 
The human melanoma cell lines SK-Mel-28, SK-Mel-103, SK-Mel-147, UACC-62, WM-
164, YUHOIN and YUHEF were selected for their genetic background, recapitulating 
the most frequent genetic alterations cutaneous melanoma (Table 3) and the mouse 
melanoma cell line B16F1 and B16F10 for their  metastatic capacity. These cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, Lonza, cat. no. BE12-
604F/U1) supplemented with 10% fetal bovine serum (FBS, Lonza, cat. no. DE14-
801F) and 100 μg/mL Penicillin/Streptomycin (Invitrogen, cat. no. 15070-063) or 
Gentamicin (Sigma Aldric, cat. no. G1272) 50 μg/mL. YUHOIN and YUHEF were 
cultured in Opti-MEM® (Thermo Fisher, cat. no. 51985026) supplemented with 5% 
FBS and 100 μg/mL Penicillin/Streptomycin. 
 
Cell Line BRAF NRAS PTEN* TP53 NFI 
SK-Mel-28 V600E WT + R273H WT 
SK-Mel-103 WT Q61R + WTR WT 
SK-Mel-147 WT Q61R + WTR WT 
UACC-62 V600E WT - WT WT 
WM164 V600E WT + WT WT 
YUHOIN WT WT  nd nd  WT  
YUHEF WT WT + WT Q853/FS-indel 
 
Table 3: human melanoma cell lines used in this PhD thesis study. 
(*: protein levels, WT: wild type, R: repressed and nd: not determined) 
 
 
2. Vector cloning 
 
2.1 LRP2 shRNA 
For LRP2 gene silencing, sense and antisense synthetic oligos were designed following 
TRC Laboratory Protocols: Forward Primer (CCGGCGGGATTTGTTAATTGGTGATCTCG 
AGATCACCAATTAACAAATCCCGTTTTTG). Reverse Primer 
(AATTCAAAAACGGGATTTGTTAATTGGTGATCTCGAGATCACCAATTAACAAATCCCG).  
Briefly, pLKO vector was digested using AgeI and EcoRI at 37ºC for 4 hours in the 
presence of NEBuffer Cutsmart (NEB Inc, cat. no. B7204S). Oligos were annealed in the 
presence of NEBuffer 2 (NEB Inc, cat. no. B7002S) incubated for 4 min at 95ºC and 
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allowed to cool to room temperature.  For the ligation, annealed oligos were diluted 
100 fold and 1 ul was used for the reaction with T4 DNA Ligase (NEB Inc, cat. no. 
M0202). For bacterial transformation Stbl3 cells were used (Thermo Scientific, cat. no. 
C737303). Plasmid isolation was performed following manufacturer instructions 
(QIAGEN-tip 500, cat. no. 10063).  Insertion was checked by DNA sequencing.  
 
3. Gene Silencing 
 
3.1 Lentiviral transduction of shRNAs 
RAB7 and RAB27 expression was inhibited by lentiviral-driven gene silencing using 
two previously reported shRNAs, Target sequences were; shRAB7a: 
GAAACAAGATTGACCTCGAAA (Sigma-Aldrich-TRCN0000007998) and shRAB27a: 
GCTGCCAATGGGACAAACATA (Sigma-Aldrich-TRCN0000005297).  For genetic 
inactivation of human LRP2, target sequences were: shLRP2 
CGGGATTTGTTAATTGGTGAT. As control, non-targeting shRNA from Sigma: 
CAACAAGATGAAGAGCACCAA was used. Viruses were produced in HEK 293FT cells 
and infections were performed as previously described263. Downregulation efficiency 
was determined after puromycin selection (1µg/mL) (Sigma-Aldrich, cat. no. P-8833) 
by protein immunoblotting. Unless otherwise indicated, cells were plated for 
expression and functional assays after puromycin selection (1µg/mL), at day 6 post-
lentiviral infection. 
 
3.2 siRNA mediated gene silencing 
Cells were transfected with specific short interfering RNA (siRNA) molecules using 
Lipofectamine 3000 Transfection Reagent (Invitrogen, cat. No. L3000008) according 
to manufacturer´s protocol. Specifically, for downregulation of  LRP2264. at a final 
concentration of 100nM ON-TARGETplus SMART pools were used (Dharmacon 
Thermo Scientific, cat. no. L-003714-00-0005 and L-012673-00-0020, respectively). 
100nM final concentration siGENOME Non-Targeting siRNA #1 (cat. No. D-001210-01-
20) was used as control siRNA. Expression analyses were performed at 72 hours for 
LRP2, by protein immunbloting. 
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4. Protein Immunoblotting 
 
Cells were harvested and total cell lysates were obtained using 1X Laemmli buffer 
(62.5 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol and 5% β-mercaptoethanol) and 
boiled at 99°C for 10 minutes. Protein concentrations were determined using the Bio-
Rad Protein Assay (Bio-Rad Laboratories) according to manufacturer’s protocol. 
Protein immunoblots were performed by standard SDS-PAGE electrophoresis in 6, 8, 
10 or 12% polyacrylamide gels and subsequently transferred to Immobilon-P 
membranes (Millipore) using Mini Trans-Blot Cell system (Bio-Rad Laboratories). 
Transfer was performed at 100V during 1 hour at 4°C. Membranes were blocked with 
5% milk in tris-buffered saline with 0.05% Tween-20 (TBS-T) for 1 hour at RT. 
Primary and secondary antibodies were diluted in 5% milk TBS-T incubated overnight 
at 4°C or 1 hour at room temperature. Primary antibodies used were: RAB7a (Sigma-
Aldrich, cat no, R8779), RAB27a (Sigma-Aldrich, cat no, HPA001333), LRP2 
(Proteintech Group, cat no, 19700-1-AP), SMPD1 (Santa Cruz Biotechnology, cat no, 
SC-293189), GBA (Sigma-Aldrich, cat no, G4171), FLOT1 (Abcam, cat no, ab133497), 
Rho-GDI (Santa Cruz Biotechnology, cat no, SC-360) Tubulin (Sigma-Aldrich, cat no, 
T9026) and Actin (Sigma-Aldrich, cat no, A5441). HRP-conjugated secondary 
antibodies used were anti-mouse and anti-rabbit (GE Healthcare, cat no, NA934) or 
anti-mouse (GE Healthcare, cat no, NA931). When indicated, image J software was 
used to quantify protein band intensities.  
 
5. Cell Immunofluorescence 
 
5.1 Immunofluorescence on fixed cells 
Cells were cultured on coverslips and fixed with 4% paraformaldehyde in PBS at room 
temperature  for 15 min. Then,  cells were then washed twice with 0.1M glycine in PBS 
for 10min each, permeabilized with 0.1% Triton X‐100 in PBS for 10 min, washed 
twice with PBS and incubated with 1% BSA in PBS at room temperature for 30 min. 
Fixed cells were incubated with primary antibody diluted in blocking buffer (1% BSA 
in PBS) over night at 4ºC Cells were then washed three times with PBS and incubated 
with Invitrogen´s Alexa‐conjugated secondary antibodies at room temperature for 1h. 
Cells were washed 3 times with PBS and counterstaining of nuclei with 4,6-diamidino-
2-phenylindole (DAPI) and mounting of the cover slips were done with Prolong Gold 
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(Invitrogen, cat. No. P36930) 20 minutes before imaging. Negative controls were 
obtained by omitting the primary antibody. The following primary antibodies and 
reagents were used: LRP2 (Proteintech Group, cat no, 19700-1-AP), Lysenin (Sigma-
Aldrich, cat no, S7651), and lysenin Antiserum (Peptanova, cat. no. 14802-v). Lysenin 
and Lysenin antiserum were used for sphingolipid staining . Alexa Fluor 555 anti‐
rabbit IgG (Invitrogen, cat no, A-31572) Alexa Fluor 555 anti‐goat IgG (Invitrogen, cat 
no, A-21432) and Alexa Fluor 488 anti‐mouse IgG (Invitrogen, cat. No. A-21202) were 
used as secondary antibodies.  
 
5.2 Visualization of cellular organelles: Lysosomes, Mitochondrias, and Ceramide 
Positive Vesicles 
 
In order to asses changes in subcellular compartments after depletion of RAB7 or 
RAB27 in live cells several fluorescence probes were employed: LysoTracker Red 
(Invitrogen, cat no, L-7528) , Mitotracker Red (Invitrogen, cat no, M-7512) and NBD-
C6-Ceramide complexed with BSA (Thermo Scientific, cat no, N1154) For the 
visualization of lysosomes mitochondria and ceramide positive vesicles respectively. 
 Briefly, fluorescence probes  were added to live cells for 1 hour, then medium was 
change before imaging under  a Nikon ECLIPSE TiE fluorescence microscope (Izasa, 
Barcelona, Spain) or TCS-SP5-WLL (AOBS-UV) spectral microscope (Leica 
Mycrosystems, Wetslar, Germany) or fixing with 4%PFA for 15 minutes at room 
temperature. All experiments were performed in duplicates and were repeated at least 
twice. 
 
For double immunostaining NBD-C6-Ceramide and LRP2. Regular protocol for live 
cells visualization was followed by cell fixation and regular protocol of 
immunofluorescence on fixed cells but without permeabilization. 
 
6. Transmission Electron Microscopy 
 
 
2*105 cells with their corresponding shRNA  were rinsed with PBS, fixed in 3% 
glutaraldehyde buffered to pH 7.4 PBS1X  for 1 hour at room temperature, and 
subsequently postfixed in osmium 1% ferricyanide 0.8% and kept at 4ºC for 1 hour. 
Fixed samples were dehydrated in a series of graded ethanol and embedded in LX 112 
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resin (Ladd Research Industries). Then, the block was sectioned at 60‐100 nm 
ultrathin sections and allocated on copper grids. Sections were stained with 2% uranyl 
acetate and lead citrate. Electron micrographs were acquired with a JEOL-1230 
transmission electron microscope at 80KV (JEOL, USA) and a 16x16 TVIPS TemCam-
F416 CMOS camera. 
 
7. Cell Proliferation Assays 
 
7.1 Growth Curves 
 
2x103 cells were plated in 96-well optical bottom plates at day 6 after lentiviral 
transduction of the indicated shRNAs. At the indicated time intervals (Day 0 is the 
following day after seeding), cells were fixed with 4% paraformaldehyde (Electron 
Microscopy Sciences, cat no, 15750) and stained with DAPI (Sigma-Aldrich, cat no, 
D9542). For each time point, total cell number was quantified in triplicates by 
automated high throughput confocal detection of DAPI-stained nuclei using the 
OPERA HCS platform and the Acapella Analysis Software (Perkin Elmer). 
 
7.2 Colony Formation 
 
High and low confluency colony formation assays were performed by seeding 5X104 
and 5x103 cells per well respectively onto 6-well plates. Cells were allowed to grow 
for 5-14 days, for subsequent fixation with cold methanol for 10 minutes. Colonies 
were stained with 0.4g/L crystal violet (Sigma-Aldrich, cat no, C3886). The number of 
colonies were quantified from micrographs of the plates using the ImageJ software. 
Unless otherwise indicated, all proliferation, assays were done in triplicates and were 
repeated at least twice. Pooled data are presented as means ± SEMs of two 
independent experiments performed with three replicates each. 
 
7. 3 Cell Cycle Analysis by Flow Cytometry 
 
For Cell Cycle analysis, exponentially growing control or shRAB7 and shRAB27 
depleted human melanoma cell lines cells were incubated with 10µM BrdU (Sigma-
Aldrich, cat no, B9285).for one hour. Cells were fixed with ice cold 70% ethanol and 
processed following the acidic protocol described before265. S-phase BrdU positive 
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cells were stained with FITC-conjugated anti-BrdU antibody (BD Biosciences, cat no, 
556028), and DNA was counterstained with 50µg/mL propidium iodide (Sigma-
Aldrich, cat no, P4170). Data was acquired using a FACS Calibur flow cytometer 
(Becton Dickinson). Cell aggregates were excluded using pulse processing and a 
minimum of 10000 single events were measured. Data were analyzed using FlowJo 
9.6.4 software (Treestar).  
 
9. TMRE Apoptotic Assay 
 
Supernatants and cells were collected, pelleted by 5 minutes centrifugsation at 1200 
rpm.  Then, resuspende pellet in TMRE 40nM (Sigma Aldrich, cat no. 87917) Incubate 
10 min at 37ºC, add pbs, centrifuge,aspirate supernatant and resuspend pellet in 400ul 
of PBS and 2ul of DAPI (Sigma-Aldrich, cat no, D9542) just before Flow Cytometry 
analysis with FACS Calibur flow cytometer (Becton Dickinson). Data were analyzed 
using FlowJo 9.6.4 software (Treestar).  
 
10. Animal Experiments 
 
 
Mouse xenograft models were generated by subcutaneous implantation of 1x106 
B16F1 cells in C57BL/6 female mice (Charles Rivers). Cells were harvested at day 6 
after infection  with control or RAB7/RAB27 shRNAs, resuspended in PBS  at 1:3 ratio 
and injected in the back of the animals (n=7 per group). Tumor growth was measured 
blinded to the experimental conditions at the indicated time intervals. Tumor volume 
was estimated using a caliper and calculated as V= axb2xπ/6, where “a” stand for the 
bigger and “b” for the smaller diameter of the tumor. All experiments with mice met 
the Animal Welfare guidelines and were performed in accordance with protocols 
approved by the Institutional Ethics Committee of CNIO. 
 
11. Mitochondrial Respiration 
 
5x103cells of RAB7 and RAB27 deficient SK-Mel-103 and UACC-62 cells with the 
corresponding shControl cells were plated per well in XF 96-well microplates and 
incubated for 24 hr at 37 °C in 5% CO2. Respiration was measured under basal 
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conditions, and in response to Oligomycin  an ATP synthase inhibitor; 0.5 μM (Sigma 
Aldrich, cat. no. 75351) and the electron transport chain accelerator ionophore FCCP  
(Trifluorocarbonylcyanide Phenylhydrazone); 0.5 μM (Quimigen S.L., cat. no. SC-
203578). Finally, respiration was stopped by adding the electron transport chain 
inhibitors Rotenone and Antimycin A (Sigma Aldrich, cat. no. R8875 and A8674 
respectively); 1 μM each. Oxygen consumption rate (OCR) and extra-cellular 
acidification rate (ECAR) were measured with a XF96 Extracellular Flux Analyzer 
(Seahorse Biosciences) following manufacturer instructions OCR and ECAR values 
were normalized to cell number. Four technical replicates per condition were used in 
three independent experiments.  
 
12. Detergent Resistant Membrane Isolation 
 
A confluent 15 cm dish was scrapped with DRM Buffer (25Mm MES, Sigma Aldrich cat 
no. M-8250) pH7.2 0.15M NaCl, Triton X-100 1%, Sigma Aldrich, cat. no. T9284 and 
protease inhibitor,  Roche Diagnostics GmbH, cat no, 11836170 001) and centrifuged 
10 mins at 13000 rpm 4ºC. A continuous sacarose gradient 5-40% was formed in an 
adaptor tube of a 40 Ti rotor and 1 ml of the protein extracts was layed in the bottom 
part. Gradient was centrifuged overnight at 200.000g and 12 fractions were collected 
by pipetting into a 2 ml eppendorf, 1 volume of acetone was added to each tube and 
samples were left at -20ºC 4hr for protein precipitation. Samples were centrifuged 10 
mins at 13000 rpm 4ºC, supernatant discarded and tubes were left opened for air-dry 
overnight. Next day each fraction was resuspended in 80 ul of Laemmli buffer and run 
in a precast gel (Bio-Rad Laboratories, cat no. 161-1123).  
 
13. Drug Treatments 
 
SMPDI inhibitor, Siramesine was used as a concentration of 4μM (Sigma Aldrich, cat. 
no. SML0976) for 24 hr.  Cell Titer Kit (Promega cay. no. G7571) was used to determine 
a sublethal concentration of this drug at mentioned time point.  GBA inhitor, 
Condutirol B Epoxide (Santa Cruz Biotechnology cat. no. SC-201356) was used as a 
concentration of 500μM for cell line UACC-62 and 100μM for cell line SK-Mel-28. 
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14. Protein Secretion Assays 
 
Conditioned media was prepared by plating 1.5x106 cells of each condition and 6hr 
later incubate with serum-free DMEM for 24 hours. Conditioned media was harvested, 
clarified by centrifugation 2000g for 10 minutes, and then concentrated in Amicon 
Ultra-15 centrifugal filter devices with Ultracel-3 membrane 3kDa NMWL (Millipore, 
Bedford, MA, USA) by centrifugation at 5000g for 2h in a swinging bucket rotor. For 
matrigel invasion assays with conditioned medium the final concentrated volume, 
500ul was used when indicated, Protease inhibitor (Roche Diagnostics GmbH, cat no, 
11836170 001) was added to the serum-free DMEM to avoid protein degradation only 
in the conditioned medium concentrated for proteomic analyses or ELISA.  
 
For LRP2 detection in the concentrated secretome from melanoma cells depleted of 
RAB7 or RAB27 a commercial Sandwich ELISA Kit was obtained (LSBio, cat no. LS-
F11978) and manufacturer instructions were followed. 
 
15. Exosome Purification 
 
Exosome purification form cell culture supernatants after RAB7 and RAB27 depletion  
was performed following a protocol described before266. Briefly, cells were cultured in 
media supplemented with 10% exosome-depleted FBS. FBS was depleted of bovine 
exosomes by ultracentrifugation at 100,000g for 16 hour. Supernatant fractions 
collected from 24 hour cell cultures were pelleted by centrifugation at 2000g for 10 
min. The supernatant was centrifuged at 10,000g for 30min. Exosomes were then 
harvested by centrifugation at 100,000g for 70 min using SW28 rotor. The exosome 
pellet was washed in 12 ml of PBS and collected by ultracentrifugation at 100,000g for 
70 min using SW40Ti rotor.  The exosome pellet was resuspended in 40ul PBS  and 
collected for further assays. The LM10 nanoparticle characterization system 
(NanoSight) was used for size characterization of the vesicles. Next,  LRP2 content in 
those exosomes was determined by ELISA. 
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16. Matrigel Invasion Assays 
Cells were serum-starved overnight and were seeded in serum-free DMEM or 
(concentrated serum-free conditioned medium from cells infected with shRAB7 or 
shRAB27) onto the upper Boyden Chamber (0.8µm BD BioCoat™ Matrigel™ Invasion 
Chambers; from BD Biosciences, San Jose, CA, USA cat. no. 354234). DMEM containing 
10% FBS was placed in the lower chamber. After incubation for the indicated time 
intervals, invading and non-invading cells were first fixed with 4% paraformaldehyde 
and then stained with DAPI. Single cells were visualized by confocal detection of DAPI-
stained nuclei through the 20x objective of a TCS-SP5-WLL (AOBS-UV) spectral 
microscope (Leica Mycrosystems, Wetzlar, Germany). The transwell membrane was 
also visualized by laser reflection. LAS AF Matrix screening Software was used for an 
automated high-throughput acquisition across the total width of the matrigel 
membrane in 4 different fields per experimental condition. IMARIS 6.3 Software was 
used to quantify the % of invading cells (normalized to the total cell number per field). 
Data are presented as means ± SEMs of three independent experiments performed in 
duplicates. 
17. Reconstructed Skins 
 
The reconstructed skins in vitro were prepared in two steps. First, the dermal 
compartment was prepared using type-1 collagen gel and 20 × 104 human 
fibroblasts/dermis. After polymerization, 25 × 104 human keratinocytes, 0.83 × 104 
human melanocytes and 10 × 104 melanoma cells (WM164) were seeded on top of 
each lattice and the skins were kept submerged in the culture medium for 24 h. 
Subsequently, theculture was raised and maintained at the air–liquid interface for 11 
days to allow complete keratinocytes stratification and differentiation267–270.  
 
The reconstructed skins containing melanoma cells were treated with concentrated 
conditioned medium obtained from melanoma cell lines Sk-Mel-28 or UACC-62 
silenced for Rab7 or Rab27 every 72 h. 
 
For Hematoxilin & Eosin visualization, skin samples were fixed in bufferen formalin, 
followed by dehydration, cleaning for paraffin inclusion and stained with H&E for 
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morphological analysis. All images were obtained by optical microscopy and analyzed 
by the NISElements software (Nikon Instruments, Melville, NY, USA). Measurement of 
melanoma area thickness was carried out with five measurements per skin from three 
independent samples. 
 
 
18. Proteomics 
 
18.1 Secretome 
 
Cell culture supernatants from two melanoma cell lines (SK-Mel-103 and UACC62) at 
6 days upon RAB7 or RAB27 genetic inactivation were collected as described above, 
and subjected to MS analysis. 
 
18.2 LC-MS/MS analysis  
 
Concentration of secreted proteins was determined using the Pierce® 660nm Protein 
Assay (Bio-Rad) using BSA as standard. Then, the samples were diluted in UT buffer 
(8M urea in 100 mM Tris-HCl, pH=8.01) and digested by means of the standard FASP 
protocol271. Briefly, samples were reduced with 10 mM DTT, alkylated using 50 mM 
IAA for 20 min in the dark. Secreted proteins were digested with Lys-C (Wako) (1:50) 
overnight, and then, diluted in 50 mM ammonium bicarbonate to reduce the urea 
concentration less than 1M and subsequently digested with Trypsin (Promega) 
(1:100) o/n at 37 °C during 6h. Resulting peptides were desalted and dissolved in 30 
µL of 0.1% formic acid (FA).  
 
18.3 Peptide analysis by nanoLC-MS/MS.   
 
Peptides were separated by reversed-phase chromatography using a nanoLC Ultra 
system (Eksigent), directly coupled with a LTQ-Orbitrap Velos instrument (Thermo 
Fisher Scientific) via nanoelectrospray source (ProxeonBiosystem). Peptides were 
loaded onto the column (RP ReproSil Pur C18-AQ 1.9 µm 400 x 0.075 mm home-made 
column), with a previous trapping column step (NS-MP-10 BioSphere C18 5 µm 120 Å 
360/100 µm, L=20 mm, Nanoseparations), during 10 min with a flow rate of 2.5 
µl/min of loading buffer (0.1% FA). Elution from the column was made with a 120 min 
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linear gradient (buffer A: 4% ACN, 0.1%FA; buffer B: 100% ACN, 0.1%FA) at 300 
nL/min. The peptides were directly electrosprayed into the mass spectrometer using 
a PicoTip emitter (360/20 OD/ID µm tip ID 10 µm, New Objective) a 1.4 kV spray 
voltage with a heated capillary temperature of 325°C and S-Lens of 60%. Mass spectra 
were acquired in a data-dependent manner, with an automatic switch between MS and 
MS/MS scans using a top 20 method with a threshold signal of 800 counts. MS spectra 
were acquired with a resolution of 60000 (FWHM) at 400 m/z in the Orbitrap, 
scanning a mass range between 350 and 1500 m/z. Peptide fragmentation was 
performed using collision induced dissociation (CID/CAD) and fragment ions were 
detected in the linear ion trap. The normalized collision energy was set to 38%, the Q 
value to 0.25 and the activation time to 10 ms. The maximum ion injection times for 
the survey scan and the MS/MS scans were 500 ms and 100 ms respectively and the 
ion target values were set to 1E6 and 5000, respectively for each scan mode.  
 
18.4 Data analysis of Secretome 
 
Raw files were analyzed either with Proteome Discoverer (version 1.4.1.2), and with 
by MaxQuant (v 1.5.1.2)272,273, against a forward-reverse concatenated database 
including human proteins (UniProtKB/Swiss-Prot, December 2013, 20.584 
sequences) and common contaminants. MaxQuant was used for protein quantification 
using Label free approach, while Protein Discoverer was used only for protein 
identification. Carbamidomethylation of cysteines was considered as fixed 
modification whereas oxidation of methionines was set as variable modifications in 
both Sequest HT and Andromeda search engine (v2.2). Sequest HT, in conjunction with 
Percolator provided the list of proteins for Proteome Discoverer. Minimal peptide 
length was set to 6 amino acids and a maximum of two missed-cleavages were allowed. 
Peptides were filtered at 1% FDR. For protein assessment in MaxQuant, at least one 
unique peptide provided by Andromeda search engine3 with a FDR = 1% was required 
for both identification and quantification, other parameters were set as default. 
Afterwards, the “proteingroup” file was uploaded in Perseus (v1.5.1.6)4. After 
removing proteins annotated as contaminants, only identified by site and/or reversed, 
the missing values of the matrix were imputed as a normal distribution assuming low 
intensity values. Then, a two-sample Student’s T-Test (FDR≤ 0.05, s0 >0.1) was 
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performed on proteins containing 100% of valid values in at least one group. Only 
significant proteins were considered as regulated.  
18.5 Intracellular Fraction (iTRAQ) 
 
Melanoma cell pellets from two melanoma cell lines (SK-Mel-103 and UACC62) 
were collected 6 days upon RAB7 or RAB27 genetic inactivation and subjected to 
proteome analysis by iTRAQ.  
 
18.6 Sample Preparation 
 
 Pellets were lysed using 7 M urea, 2 M thiourea, 100 mM Hepes pH 7.5, 1:1000 (v/v) 
of benzonase and 1:100 (v/v) of HaltTM phosphatase and protease inhibitor cocktail 
100x. Samples were vortexed, sonicated and clarified by centrifugation at 4 °C and 
16,100 × g for 15 min. Protein concentration was determined using the Pierce® 
660nm Protein Assay (Bio-Rad) using BSA as standard.  
 
Samples were digested using the filter aided sample preparation (FASP) protocol271. 
Briefly, the equivalent to 60 µg of each sample was loaded on the filter, reduced with 
10 mM DTT 1 h at 37ºC in UTEAB and alkylated using 55 mM iodoacetamide for 20 
min in the dark. The excess of reduction and alkylation reagents were washed out with 
UTEAB (8M urea in 100 mM triethylammonium bicarbonate, pH=8.01). The proteins 
were digested overnight using endoproteinase Lys-C (Wako) with 1:50 enzyme to 
protein ratio. Finally, trypsin (Promega) dissolved in 0.05M TEAB was added and 
samples were subjected to a second digestion for 6 h. Each tryptic digest was labeled 
according to the manufacturer's instructions (AB Sciex) with one 8-plex isobaric 
amine-reactive tag per cell line (iTRAQ® Reagent 8plex kit). After two hours of 
incubation, labeled samples were pooled, and evaporated to dryness in a vacuum 
centrifuge. The iTRAQ sample was cleaned up using a Sep- Pak C18 cartridge for SPE 
(Waters Corp., Milford, MA). Eluted peptides were vacuum-dried.  
 
Peptides were fractionated using high pH reverse phase technique )203. Peptides were 
dissolved in 100 µl of phase A (10mM NH4OH) and eluted at a flow rate of 500 µl/min 
onto an XBridge BEH130 C18 (3.5 µm, 4.6 x 250 mm) column (Waters) during 60 
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minutes using the following gradient of phase B (10mM NH4OH, 90% CH3CN): 0-50 
min 25% B, 50-54 min 60% B, 54-61 min 70% B. 40. Fractions were collected, and 
concatenated into 15 fractions and evaporate in the speed vac. Peptides were 
resuspended in 15μl 0.1% FA. 
 
18.7 Peptide analysis by nanoLC-MS/MS 
 
The LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, Bremen) was coupled 
to an Eksigent nano LC system (Eksigent technologies) through a nanoelectrospray ion 
source (Proxeon Biosystems). Peptides were loaded from a cooled nanoLC AS-2 
autosampler (Eksigent technologies). In order to pre-concentrate and desalt the 
samples before switching the pre-column in line with the separation column, 5 μL from 
each sample was loaded onto a trapping cartridge (NS-MP-10 BioSphere C18 5 µm 120 
Å 360/100 µm, L=20 mm, Nanoseparations) during 10 min with a flow rate of 2.5 
µl/min of loading buffer (0.1% FA). The peptides were eluted from a RP ReproSil Pur 
C18-AQ 1.9 µm 400 x 0.075 mm home-made column by application of a binary gradient 
consisting of 4% ACN in 0.1% FA (buffer A) and 100% ACN in 0.1%FA (buffer B), with 
a flow rate of 300 nL/min. Peptides were separated using the following gradient: 0-2 
min 4% B, 2-133 min 30% B and 133-143 min 98% B. The column was operated at a 
constant temperature of 55ºC. The LTQ Orbitrap Velos was operated in positive 
ionization mode. The MS survey scan was performed in the FT analyzer scanning a 
window between 350 and 1500 m/z. The resolution was set to 30 000 FWHM at m/z 
400. The m/z values triggering MS/MS with a repeat count of 1 were put on an 
exclusion list for 60 s. The minimum MS signal for triggering MS/MS was set to 5000 
counts. In all cases, one microscan was recorded. HCD was used for fragmentation, up 
to the 15 most abundant isotope patterns with charge ≥2 from the survey scan were 
selected for fragmentation in the HCD collision cell. Normalized collision energy was 
set to 38.0, the Q value to 0.25 and an activation time to 0.10 ms. Waveform filter was 
activated. The resulting fragments were detected in the Orbitrap system with a 
resolution of 7500 FWHM at m/z 400. The maximum ion injection times for the survey 
scan and the MS/MS scans were 500 ms and 250 ms respectively and the ion target 
values were set to 1E6 and 7E4, respectively for each scan mode. 
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18.8 Data Processing  
 
All files were analyzed using Proteome Discoverer 1.4 (Thermo Scientific) with 
Sequest HT as the search engine against a concatenated Uniprot database of Homo 
sapiens (UniProtKB/Swiss-Prot, December 2013, 20.584 sequences and common 
contaminants), iTRAQ 8plex tag labelling in lysine and peptide N-termini were 
included as fixed modifications, together with carbamidomethylation of cysteine. 
Oxidation of methionine and iTRAQ 8plex labelling of tyrosine were included as 
variable modifications. Precursor mass tolerance was 20 ppm and fragment mass 
tolerance was 0.05 Da. The integration of reporter ions was performed using the most 
confident centroid with a tolerance of 50 ppm. PSMs were filtered using Percolator 
(v2.04) with a FDR of 1%. Quantification results at the PSM level were exported for 
further analysis. 
 
18.9 Statistical and Data analyses 
 
Quantification and statistical analysis was performed using Isobar (version 
1.10)274,275, in R (version 3.1.2 “Pumkin Helmet”), using a noise model that accounts 
for the technical variation and a second biological variability model using the two 
independent digestions of the control samples. Proteins with a p-value of less than 
0.05 and with a log2 ratio > 0.3 or < - 0.3 were classified as up- or down- regulated, 
respectively.  
 
 
19. GSEA, Heatmaps and Venn diagrams 
 
Gene Set Enrichment Analysis (GSEA)  or Single Sample GESA were performed using 
annotations from the KEGG or REACTOME pathways. Genes were ranked using the t 
statistic. After Kolmogorov-Smirnoff correction for multiple testing, only those 
pathways bearing a FDR <0.25 were considered significant276. Heatmap and 
correlation graphs for RNA and protein levels were created by Perseus v1.5.1.6. 
Protein networks were created by using Search Tool for the Retrieval of Interacting 
Genes/Proteins (STRING)277 . Venn diagrams were created by using online tools Venny 
v2.0278. 
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20. Statistical Analysis 
 
Difference on growth and invasion capacity of melanoma cells after genetic depletion 
of RAB7 and RAB27 was analyzed by ANOVA p<0.05 was considered significant and p-
values were represented in figures as follow: “***” for p<0.001, “**” for p<0.01, “*” for 
p<0.05 and “ns” for not significant.
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1. RAB7 and RAB27 are required to sustain melanoma growth. 
Previous studies have shown that RAB7104 and RAB27101 are required to maintain 
melanoma cell proliferation. However, to our knowledge, a parallel comparison of 
their role in melanoma has not been performed. Therefore, we silenced the 
expression of these genes in a panel of melanoma cell lines (Figure 7) with 
different genetic background (Table 3).   
Cells monitored at day 6 after infection by DAPI-based nuclei count (see Methods) 
showed a marked inhibitory effect of bothRAB7 and RAB27 shRNA  in cell viability 
(Figure 7B). Interestingly, albeit to different extends, all melanoma cell lines 
tested responded to RAB7 and RAB27 shRNA with decrease in inhibited 
proliferative capacity (see Figure 7C for colony formation assays). To further 
confirm the physiological relevance of these results, control, RAB7- and RAB27-
depleted mouse melanoma cells (B16F1) were injected subcutaneously into the 
flanks of 8-week-old BL6 female mice as a syngeneic mouse model. The same 
observations described in vitro were recapitulated in an immunocompetent 
mouse model (Figure 7D).  Next, in order to characterize cell cycle alterations, 
control RAB7- and RAB27-depleted human melanoma cells were stained with 
BrdU and propidium iodide, flow cytometry analysis of total DNA revealed that 
RAB7- and RAB27- shRNA cells accumulated at the G1 phase, with the 
concomitant reduction in S-phase proliferating cells in comparison with shControl 
cells (Figure 7E). Together, these in vitro and in vivo results support a relevant 
role of RAB7 and, in particular, of RAB27 on the tumorigenic potential of 
melanoma cells,  
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2. Non-equivalent roles of RAB7 and RAB27 in melanoma cell invasion and 
migration  
Interestingly, although RAB7 and RAB27 are required for cell proliferation, 
opposite roles in cell invasion has been described for them74,104. Therefore, we 
performed a parallel comparison of the effect of silencing both genes in invasion 
and proliferation. Matrigel invasion assays revealed that RAB7 downregulation 
enhanced the invasiveness of low-metastatic cell lines, while RAB27 silencing had 
no effect (Figure 8A). However, RAB7 silencing did not enhance the metastatic 
potential of highly metastatic cell lines, while RAB27 depletion decreased their 
invasive capacity (Figure 8B). Equivalent results were obtained in a wound 
healing assay with mouse melanoma cell lines (Figure 8C). These data confirms 
non-equivalent roles of vesicular trafficking modulators RAB7 and RAB27 in 
melanoma invasion and migration.  
3. Different cytoplasmic alterations induced by RAB7 or RAB27 silencing  
Invasion capacity is directly linked to the cell ability to migrate. Since there is a 
corollary of studies suggesting that vesicular trafficking is essential for cell 
migration279–281, we hypothesized that depletion of RAB7 or RAB27 might be 
affecting vesicular trafficking pathways in a different manner and, in turn, 
affecting the  cellular  invasion capacity. As expected, microscopy-based cell 
observation showed marked morphological changes in RAB7‐depleted melanoma 
cells, most frequently leading to dendrification or to prominent cytosolic 
vacuolization. However, alterations induced by RAB27 downregulation were very 
different: cells were more rounded and had lost their dendrification. (Figure 9A).  
Figure 7 (Page 64). RAB7 and RAB27 are required to sustain melanoma growth. 
 A, Downregulation of RAB7 and RAB27 in a panel of human melanoma cell lines, by lentiviral-
based transduction of shRNA constructs visualized by immunoblotting compared to cells expressing 
control shRNA. B, Impaired growth of human melanoma cell lines upon RAB7 or RAB27 depletion. 
Time points indicate the days after seeding. C, Colony formation of the cell lines in (A) determined 
by crystal violet 14 days after seeding. Quantification shown below, (ratio of inhibition with respect 
to control shRNA-transduced cells). D, Growth of allografts generated with the indicated mouse 
melanoma cell line after subcutaneous implantation in B16 mice. E, Relative cell numbers at different 
phases of the cell cycle of the cell lines in (A) upon RAB7 or RAB27 depletion compared to control 
cells. Error bars correspond to SEM of at least two experiments. “***”p<0.001, “**”p<0.01, 
“*”p<0.05 and “ns” not significant. 
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Subsequently, we took advantage of Transmission Electron Microscopy (TEM) to 
acquire a global view of the morphological changes induced by either RAB7 or 
RAB27 depletion on two melanoma cell lines silenced for either gene. We chose 
SK-Mel-103 and UACC-62 as representative cell lines for the different genetic 
background and because of the differential changes upon RAB7 or RAB27 
depletion (Figure 8A and B). As expected, we observed different ultrastructural 
changes: RAB7 depletion caused large vacuolization and lysosomal accumulation 
in the cell cytoplasm.  On the other hand, RAB27 depletion caused increased 
microvesicle formation and general membrane disruption (Figure 9B).  
 
 
Figure 8. Non-equivalent roles of RAB7 and RAB27 in melanoma cell invasion and migration. 
A, Invasiveness of low invasive cell lines expressing Control shRNA or an shRNA directed against  
RAB7 or RAB27, evaluated by Matrigel invasion assay (72 hr). B, Invasiveness of highly invasive 
cell lines expressing Control shRNA or an shRNA directed against RAB7 or RAB27, evaluated by 
Matrigel invasion assay (12 hr). C,  Total area covered in 10 hr in a wound healing assay by two 
mouse melanoma cell lines upon RAB7 or RAB27 depletion compared with shControl cells. 
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In order to confirm TEM results that suggest accumulation of lysosomes upon 
RAB7 depletion, we stained the cells with the acidic dye LysoTracker and 
observed different mobilization of lysosomes upon RAB7- but not upon RAB27- 
depleted cells compared to control.  Lysosomes shifted from the perinuclear 
region towards the cell periphery upon RAB7 depletion (Figure 9C) being the 
Figure 9. RAB7 or RAB27 silencing induce different cytoplasmic alterations.  
A, Representative micrographs showing morphological changes induced by RAB7 or RAB27 
shRNA in a panel of melanoma cell lines with different genetic backgrounds. B, Representative 
micrographs of Electron microscopy of cells silenced of RAB7 and RAB27 compared to control 
cells. C, Confocal visualization of cells labelled with the acid-dependent LysoTracker fluorescent 
probe. Dashed white line indicates cell boundaries.  Average distance in pixels of lysosomes to 
the nucleus is indicated below. D, Sum of lysosomes per cell, black bar indicates mean value. 
“***”p<0.001“**”p<0.01, “*”p<0.05 and “ns” not significant. 
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number of lysosomes also increased (Figure 9D).  These results reinforced the 
non-equivalent function of these two RAB proteins in the regulation of vesicular 
trafficking pathways in melanoma. 
4. Proteomic Analysis (iTRAQ LC-MS/MS) for the identification of deregulated 
pathways  
Vesicle trafficking plays a critical role in maintaining cell homeostasis282,283. In 
order to have a global view of all pathways affected by the alterations introduced 
in the vesicular trafficking pathways we performed a global proteomic analysis of 
the intracellular fraction of two melanoma cell lines (UACC-62 and SK-Mel-103) 
upon RAB7 and RAB27 depletion.  
The resulting proteomic data was filtered for proteins showing a 0.3 log2 fold 
change with respect to shRNA controls and p<0.05. 5135 proteins were detected, 
which rendered 385 and 738 distinct proteins (both downregulated and 
upregulated) in UACC-62 and SK-Mel-103, respectively, upon RAB7 depletion. 
More changes were observed upon RAB27 depletion, which might be a reflection 
of the drastic changes observed by TEM: 1483 and 1182 distinct proteins in SK-
Mel-103 and UACC-62 (Figure 10A).  We actually observed a significant overlap of 
protein changes induced by silencing of either gene in both cell lines: r=0.31 for 
shRAB7 and r=0.41 for RAB27. (Figure 10B). Full list of upregulated or 
downregulated genes in both cell lines upon RAB7 or RAB27 depletion are listed 
in Annex 1 and Annex2 respectively. Enrichment analyses using KEGG database 
revealed a preferential downregulation for biological processes related to 
proliferation, such as DNA replication and cell cycle, common to the depletion of 
both genes. (Figure 10C top).  We also observed differential enrichment of 
pathways related to vesicle trafficking. Some of the pathways enriched upon RAB7 
depletion, such as Cell Adhesion Molecules, ECM interaction, Focal adhesion and 
lysosomal proteins, were not altered upon RAB27 depletion. The opposite was 
observed in the case of other pathways such as proteosome and TOLL, NOD and 
RIG receptor pathways (Figure 10C medium).  Interestingly, we also observed 
changes in lipid metabolism pathways. Particularly, a strong enrichment in 
sphingolipid metabolism pathways was observed upon RAB7 depletion, being the 
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pathway unaltered upon RAB27 depletion (Figure 10C lower). Full list of 
pathways enriched upon RAB7 or RAB27 depletion are listed in Annex 3.  Gene Set 
Enrichment Analyses were performed to check that enrichments observed in 
Figure 10C were statistically significant and identify the genes  in each category. 
(Figure 10D). Together these results support the non-equivalent role of RAB7 and 
RAB27 in controlling different cellular pathways with a particular focus in lipid 
metabolism pathways. 
  
Figure 10. Proteomic Analysis (iTRAQ LC-MS/MS) identifies the deregulation of pathways 
upon RAB7 or RAB27 depletion. A, Volcano Plots showing up- and downregulated proteins 
identified by iTRAQ LC-MS/MS analysis in SK-Mel103 and UACC-62 cells upon shRAB7 and 
shRAB27 transduction. Factors indicated in green and red are those with a significant changes in 
protein expression (FC >=0.3 and p<0.05) B, Correlation scatter plots of global changes in protein 
levels upon RAB7 and RAB27 depletion.  C, Enriched biological processes identified from changes 
in the proteome of the indicated cell lines defined by KEGG database. D, Enrichment plots for 
representative pathways depicted in C, GSEA FDR(<0.05) 
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5. RAB7-rewiring of sphingolipid metabolism towards ceramide production 
We were intrigued by the alterations observedin sphingolipid metabolism caused 
by RAB7 depletion. Thus, we searched for proteins implicated in this pathway that 
were upregulated in both cell lines   and we identified two lysosomal enzymes that 
mediate the transformations of sphingolipids into ceramide: Glucosylceramidase 
(GBA)284  and Acid Sphingomyelinase (SMPD1)285 (Annex 4).  
 
Next, we confirmed proteomics results by evaluating the changes in the protein 
levels of SMPD1 and GBA upon shRAB7 and shRAB27 by immunoblot in a panel of 
melanoma cell lines. Despite some intrinsic-cell line variability we observed an 
increase in the levels of SMPD1 and GBA upon RAB7 depletion across all the cell 
lines tested, (Figure 11A). Next, we tested if those changes in protein levels 
Figure 11 RAB7-rewiring of sphingolipid metabolism towards Ceramide production.   
A, Immunoblots showing changes in SMPD1 and GBA upon RAB7 and RAB27 depletion in a panel 
of melanoma cell lines. B, Changes in intracellular ceramide content labeled with NBD-C6-
ceramide. Scale bar 10um. C, Quantification of number of ceramide positive vesicles per cell in the 
melanoma cell lines SK-Mel-103 and UACC-62. Error bars correspond to SEM of at least two 
experiments in duplicates. “***”p<0.001, “**”p<0.01, “*”p<0.05 and “ns” not significant. 
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translated into alterations in ceramide levels by using the fluorescent probe C6- 
Ceramide and we observed an increase in the number of ceramide positive 
vesicles scattered throughout the cytoplasm caused by RAB7 depletion but not 
upon RAB27 depletion (Figure 11B and C).   
6. RAB7-depletion does not induce melanoma cell death 
As ceramide is considered a classical apoptosis inductor286,287, we evaluated cell 
death by a flow cytometry based TMRE mitochondrial membrane potential assay. 
Interestingly, RAB7 depletion did not caused any difference in cell death 
compared with control cells, while there was a significant increase in apoptosis 
upon RAB27 depletion (Figure 12A). One of the mechanism described for 
ceramide-mediated induction of cell death is by triggering pore formation in the 
mitochondrial outer membrane, which causes the reduction of the membrane 
potential, leading in turn to cytochrome C release and apoptosis induction. In 
order to see if this increment in cellular ceramide is affecting mitochondrial 
homeostasis we stained the cells with the red fluorescent probe MitoTracker 
(Figure 12B). Although there were no changes in mitochondrial network in 
shRAB7 cells compared with the control, shRAB27 cells mitochondrial network 
was totally disorganized. Subsequently, we evaluated the mitochondrial OXPHOS 
activity using the Seahorse technology. As expected, mitochondrial potential and 
activity was not affected by shRAB7 but was reduced by shRAB27 (Figure 12C and 
D). Together, these data suggest that intracellular ceramide accumulation induced 
by RAB7 depletion is not triggering cell death, while depletion of RAB27 is 
inducing apoptosis, further reinforcing the non-equivalent role of these two 
proteins in melanoma.  
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7. shRAB7 rewiring of sphingolipid metabolism and invasion is dependent of 
SMPD1 and GBA 
We were intrigued by the fact that melanoma cells silenced for RAB7 are more 
metastatic while having elevated expression of these enzymes and higher 
ceramide content. Recent studies have described novel  functions of ceramide not 
related with cell death but with tumour progression, cell-cell communication and 
metastasis153,288.  Therefore, we interrogated TCGA database and we observed 
that among cutaneous melanoma patients (n=486) those with higher mRNA 
levels of either SMPD1 or GBA had worse survival that those with lower 
expression levels of those genes. On the other hand, the reverse behaviour was 
observed in other tumour types such as Pancreatic Adenocarcinoma, or no 
Figure 12 RAB7 depletion does not induce melanoma cell death. A, Flow cytometry TMRE 
analysis of cell death  upon RAB7 and RAB27 depletion. Percentage of apoptotic cells is highlited 
in red. B, Mitochondrial network stained with red fluorescent probe mitotracker in melanoma cells 
upon RAB7 and RAB27 depletion. C,  Mitochondrial activity in melanoma cells upon RAB7 or 
RAB27 silencing determined by oxygen consumption rate (OCR) utilizing the Seahorse XF96 
Extracellular Flux Analyzer (Seahorse Bioscience). OCR was measured as pmol/min/cells (5x103) 
in four technical replicates at basal conditions and after the administration of the indicated 
compounds (n=3). D, Cell Respiratory Control Ratio from  Seahorse experiment in (C). Results are 
mean ± SEM. Error bars correspond to SEM of three experiments in duplicates. “**”p<0.01, 
“*”p<0.05 and “ns”not significant. 
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differences in overall survival in the case of breast and lung adenocarcinoma. 
(Figure 13A).  
Fig 13 shRAB7 rewiring of sphingolipid metabolism and invasion is dependent on SMPD1 and 
GBA .  A, Overall survival of patients from different tumor types separated as a function of high 
(10% highest expression) vs. low  (remaining patients) SMPD1 and/or GBA  mRNA . Indicated are 
p-values estimated with the Log-rank test  B, Left panel, titration  of  siramesine drug,  readout was 
cell viability determined by cell titer (red) and  accumulation of sphingomyelin foci determined by 
immunofluorescence (blue). C, Titration of CBE determined by a decrease in  intracellular ceramide 
intensity determined by IF of NBD-C6- ceramide.  D,  Ceramide staining  by IF using NBD-C6-
ceramide in two melanoma cell lines upon RAB7 silencing +/- Siramesine and CBE treatment for 
24 hrs. D, Matrigel invasion assay  of two melanoma cell lines upon RAB7 silencing +/- Siramesine 
and CBE pre-treatment for 24 hrs. Error bars correspond to SEM of two experiments in duplicates. 
“**”p<0.01, “*”p<0.05 and “ns” not significant. 
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Therefore, to determine if this increase in ceramide production was behind the 
increase in invasiveness observed upon RAB7 depletion, we used chemical 
inhibitors for each of these enzymes: Siramesine289 for SMPD1 and Conduritol B 
Epoxide (CBE)290 for GBA. In order to identify the optimal concentration that 
would block ceramide production without affecting cell viability we tittered 
Siramesine by assessing  intracellular levels of sphingomyelin (Figure 13B) while 
CBE titration was done by measuring ceramide content (Figure 13C).  Cell viability 
was not affected by CCBE even at the highest concentrations used, (data not 
shown). Moreover, treatment with both inhibitors caused a decrease in ceramide 
content as measured by immunofluorescence with C6-ceramide probe in two 
melanoma cell lines transduced with shRAB7 compared to control cells (Figure 
13D). Curiously, 24hr treatment with either Siramesine or CBE reverted the 
increase in invasiveness observed by RAB7 depletion in a matrigel invasion assay. 
(Figure 13E). These results reinforce our findings of a RAB7-dependent lineage-
specific wiring of the endolysosomal machinery in melanoma. 
 
8. Conditioned medium of RAB7-and RAB27-depleted cells have opposite effects on 
cell invasion. 
Since ceramide has also been described to influence cell-cell communication153,157, 
and some studies have described how the secretion of prometastatic proteins with 
paracrine functions are regulated by RAB proteins291,292,  we tested whether the 
condition medium of cells depleted of RAB7 and RAB27 would influence the 
invasiveness of other melanoma cell lines. Thus, we performed a matrigel invasion 
assay with a non-invasive cell line treated with conditioned medium obtained 
from cells depleted of RAB7 and RAB27 respectively. Surprisingly, cells treated 
with conditioned medium from shRAB7 cells were more invasive than cells 
treated with medium from control cells, and the opposite happened when cells 
were treated with conditioned medium from shRAB27 cells (Figure 14A). This 
observations recapitulate changes in invasiveness observated in (Figure 8A and 
B).  
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In addition, similar results were observed in an “in vitro” model of reconstructed 
human skin: WM164 cells treated with conditioned medium from shRAB7 cells 
were able to migrate deeper through the dermis while cells treated with 
conditioned medium from shRAB27 cells barely moved not being able to disrupt 
the basal layer. (Figure 14B). And importantly, treatment of shRAB7 cells with 
either Siramesine or CBE abrogated the increase in invasion capacity (Figure 14C), 
while adding the inhibitor alone, did not influence invasiveness in WM164 cell 
line. (Figure 14D). 
 
Fig 14 The conditioned media of RAB7- and RAB27-depleted cells has an opposed effect on 
cell invasion  A,  Matrigel Invasion Assay of WM164 treated with concentrated CM obtained from 
UACC-62 or SK-Mel-103 silenced of RAB7 or RAB27. (72 hr). B, H&E staining of reconstructed 
skins  with WM164 melanoma cell line treated with concentrated CM of cell line UACC-62 silenced 
for RAB7 or RAB27 expression.  Average invasion  (pixels)  of melanoma cells is indicated below. 
C, Matrigel Invasion Assay of WM164 treated with concentrated CM obtained from UACC-62 or 
SK-Mel-28 silenced for RAB7 and treated with DMSO Siramesine or CBE. (72 hr) D, Matrigel 
Invasion Assay of WM164 treated with DMSO Siramesine or CBE (72 hr). Error bars correspond 
to SEM of at least two experiments in duplicates. “***”p<0.001, “**”p<0.01, “*”p<0.05 and 
“ns”not significant. 
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9. Identification of a cluster of lysosomal proteins differentially secreted upon 
RAB7 depletion  
We hypothesized that changes in vesicular trafficking upon RAB7 depletion would 
cause a secreted factor to be responsible of the paracrine increase in invasiveness 
of other melanoma cells treated with CM of shRAB7 cells. The secreted fraction 
was collected from the same cell populations in which iTRAQ experiment was 
performed, concentrated and analysed by MS/MS as well. 489 and 791 proteins 
were differentially secreted upon RAB7 depletion in SK-MEL-103 or UACC-62 
respectively, and 677 and 1041 proteins in the case of RAB27 depletion in both 
cell lines (Figure 15A). However, we observed little overlap of secreted proteins 
induced by silencing of RAB7 gene in both cell lines (r=-0.13) while secreted 
factors changes had a more similar tendency in the case of shRAB27 in both cell 
lines (r=0.46) (Figure 15B). This difference explain why the CM of mildly invasive 
cells, RAB7-depleted, increase invasion while the CM of highly invasive cell lines. 
Did not have that effect.  
 Next, by comparing the secretome data with the intracellular proteomic results 
we identified 279 proteins that were absent in the cell extracts. Enrichment 
analyses  of the specifically secreted proteins using Gene Ontology database 
revealed  that this proteins are usually located in the extracellular space (Cellular 
Component GO)  and are involved in ECM interactions (Figure 15C).  Interestingly, 
focusing on the proteins that were more secreted in UACC-62 shRAB7 and not 
showing intracellular changes allowed us to identify a cluster of 52 proteins.   
Functional enrichment of this protein cluster was performed, and strikingly the 
most enriched categories are related to lysosomal function and location (KEGG 
and Gene Ontology category FDR >0.05) (Figure 15D Full list of functional 
enrichments is listed in Annex 5). Many lysosomal proteins such as Cathepsins and 
MMP have been linked with tumour metastasis293. Therefore, our findings support 
the prometastatic role of the conditioned medium of RAB7 depleted cells. 
Unexpectedly, the top scoring protein in that cluster was not a protease but a 
transmembrane protein termed LRP2/Megalin (Low density lipoprotein receptor 
type II).  LRP2 is a multiligand endocytic receptor located in the plasma 
membrane, but it is also annotated as endolysosomal protein294. This protein was 
VI. Results/Resultados 
 
77 
 
of particular interest because secreted forms has been described to be involved in 
several diseases such neuropathies and nefropathies294,295. In melanoma, LRP2 
expression was described to  be increased during melanoma progression296, but 
has not  been linked to RAB7 mediated trafficking or to metastasis. 
 
 
 
 
Fig 15 Identification of a cluster of lysosomal proteins differentially secreted upon RAB7 
depletion A, Volcano Plots showing up- and downregulated proteins identified by Label Free  MS 
analysis of the concentrated CM obtained from SK-Mel103 and UACC-62 cells upon shRAB7 and 
shRAB27 transduction. Factors indicated in green and red are those with a significant changes in 
protein expression (FC >=0.3 and p<0.05) B, Correlation scatter plots of changes in protein levels 
upon RAB7 and RAB27 depletion. C, Overlap between all  proteins identified in the iTRAQ 
experiment of Cell extracts and those identified in the proteomic analysis of the conditioned medium. 
Below are shown the enriched biological process and biological functions of proteins exclusively 
identified in the concentrated conditioned medium D,  Cluster of  proteins specifically secreted upon 
RAB7 depletion in UACC-62.  Right, panel  enrichment analysis  of those proteins. Lysosome GO 
category is highlighted in red 
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10.  RAB7 depletion induces LRP2 secretion in vesicles   
First we validated proteomics results by performing an ELISA of the CM from 
shRAB7 and shRAB27 melanoma cell lines. We observed higher levels of LRP2 
secretion upon RAB7 depletion compared with control cells, and the other way 
around in the case of shRAB27 in several cell lines (Figure 16A). Curiously, 
although intracellular LRP2 was not detected in the iTRAQ we could see how LRP2 
levels were also slightly increased upon RAB7 depletion while there was a clear 
reduction of LRP2 levels upon RAB27 depletion (Figure 16B).  
Next, we focused on the mechanism behind intracellular trafficking of LRP2 from 
inside the cell to the extracellular space. By double IF in fixed cells we observed 
there was an increase in the colocalization of LRP2 with ceramide positive vesicles 
upon RAB7 depletion (Figure 16D). Since ceramide is a component of membrane 
lipid rafts we purified Detergent Resistant membranes by density gradient and 
observed a partial colocalization of LRP2 with Flotilin-1  a positive marker of lipids 
rafts, and no colocalization with the the cytoplasmic marker, Rho-GDI (Figure 
16E).  Since ceramide production by sphingomyelinases has been described as a 
mechanism of ESCRT-independent exosome secretion153,157, we checked whether 
LRP2 colocalized by IF with the exosomal marker CD81 (Figure 16F). 
Furthermore, by ELISA we determined that LRP2 is found preferentially in 
exovesicles rather than in a soluble form (Figure 16G). Together, these results 
suggest the LRP2 decorates a subtype of intracellular vesicles that are secreted to 
the extracellular space upon RAB7 depletion. 
11. LRP2 as a novel prometastatic protein downstream RAB7 
Next, in order to unravel the connexion between ceramide production and LRP2 
regulation we analysed the effect of chemical inhibition of GBA and SMPD1 on 
LRP2; treatment with either CBE or Siramesine caused a decrease in endogenous 
LRP2 protein levels, measured by immunoblot (Figure 17A) and IF (Figure 17B) 
in melanoma cell lines depleted for RAB7. Subsequently, LRP2 amount in purified 
exosomes was also decreased (Figure 17C). This data uncovers a novel link of 
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regulation between sphingolipid metabolism and transmembrane protein 
regulation.  
 It has been described that melanomas acquire LRP2 expression during melanoma 
progression296. However, LRP2 mRNA levels did not predict patient prognosis or 
there were not significant changes comparing primary tumour and metastasis in 
the TCGA database297. Interestingly, patients harbouring BRAF  mutations have 
Fig 16 RAB7 depletion induces LRP2 secretion in vesicles   
A, ELISA-based quantification of LRP2 in  concentrated CM upon depletion of RAB7 and RAB27 
in UACC-62, SK-Mel-28 and WM-164 melanoma cell lines. B, Immunoblots showing changes in 
LRP2 upon RAB7 and RAB27 depletion in a panel of melanoma cell lines. C, Colocalization of 
LRP2 and ceramide in UACC-62  silenced for RAB7. Below, green signal intensity in every red dot 
(arbitrary unit)  D,   LRP2, Rho-DGI and Flotilin1 Immunoblot  of continuous fractions obtained 
from sucrose gradient centrifugation of cell lysates of UACC-62. E  LRP2 (red) and CD81 (green) 
double IF  upon  RAB7 depletion in UACC-62. Percentage of colocalization is indicated below. F, 
ELISA-based quantification of LRP2 in  exosomes or concentrated CM of UACC-62 silenced for 
RAB7 and RAB27 containing or depleted of exosomes (blue, purple and green bars respectively).  
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higher mRNA expression levels than patients with mutations in other oncogenes 
(Figure 17D) 
.  
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Therefore, we chose two BRAF mutant melanoma cell lines to perform loss-of 
function assays with a short hairpin RNA construct targeting the coding sequence 
of the LRP2 gene (Figure 17E). Consistent with reported results, LRP2 depletion 
inhibited melanoma cell proliferation (Figure 17F) and induced alterations in cell 
morphology (Figure 17G). Curiously, we also showed that LRP2 depletion (by both 
shRNA and siRNA) decreased melanoma invasion capacity assessed by matrigel 
invasion assays (Figure 17H). Supporting the paracrine pro-invasive role of LRP2, 
melanoma cells treated with CM from LRP2 depleted cells decreased their 
invasion capacity (Figure 17I). Moreover, shRAB7-mediated increase in invasion 
capacity is abrogated when LRP2 is depleted. The same effect was observed when 
a low invasive melanoma cell line was treated with CM of shRAB7 cells and LRP2 
siRNA (Figure 17J and K). 
12. Intracellular proteomic analysis (iTRAQ LC-MS/MS) upon LRP2 depletion 
identifies enrichment in cell cycle pathways. 
In order to gain insight into the mechanism of metastasis driven by LRP2 we 
performed an unbiased global analysis of cell extracts depleted by LRP2  in two 
melanoma cell lines (SK-Mel-28 and UACC-62) upon LRP2 depletion (siRNA and 
shRNA). After performing enrichment analysis, we observed a decrease in 
Figure 17. (Page 80) LRP2 as a novel prometastatic protein downstream RAB7  A Immunoblot 
of LRP2 and RAB7 levels upon DMSO, Siramesine or CBE treatment in UACC-62 and SK-Mel-28  
melanoma cell lines silenced for RAB7. B, LRP2 (red) immunofluorescence in the same conditions 
that (A) C, ELISA-based quantification of LRP2 in  exosomes of UACC-62 and SK-Mel-28 silenced 
for RAB7 upon DMSO, Siramesine or CBE treatment. D, LRP2 mRNA expression levels from 
TCGA melanoma samples categorized by  oncogene subtypes.  E, Downregulation of LRP2 in two 
melanoma cell lines by lentiviral-based transfer of an shRNA constructs visualized by 
immunoblotting with respect to cells expressing control shRNA. F, Colony formation of the cell 
populations in (D) determined by crystal violet 14 days after seeding. Left panel shows 
quantification, data are represented as the ratio of inhibition with respect to control shRNA-
transduced cells. G, Representative micrographs showing morphological changes induced by LRP2 
depletion in SK-Mel-28 and UACC-62. H, Invasiveness of two melanoma cell lines expressing 
Control shRNA or an shRNA directed against LRP2, evaluated by Matrigel invasion assay (72 hr). 
I, Matrigel Invasion Assay of WM164 treated with concentrated CM obtained from SK-Mel-28 or 
UACC-62 silenced of LRP2. (72 hr) J, Changes in invasiveness SK-Mel-28 expressing Control 
shRNA or LRP2 shRNA with or without siLRP2, evaluated by matrigel invasion assay. K, Matrigel 
invasion assay of WM164 treated with concentrated CM obtained from SK-Mel-28 silenced of 
RAB7 plus siControl or siLRP2 (72 hr). Error bars correspond to SEM of at least two experiments 
in duplicates. “***”p<0.001, “**”p<0.01, “*”p<0.05 and “ns” not significant.  
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pathways involved in cell proliferation, and protein secretion (Figure 18A). These 
results confirmed our previous findings upon LRP2 depletion (Figure 17D).  
Figure 18. Intracellular proteomic analysis (iTRAQ LC-MS/MS)  upon LRP2 depletion 
identifies enrichment  in cell cycle pathways. A,  Enriched biological process identified from 
changes in the proteome of the indicated conditions defined by REACTOME database by ssGSEA. 
B, Venn diagram showing overlap between downregulated genes  obtained in both  Proteomics 
experiment upon LRP2  or RAB7 depletion. C,  List of shared proteins identified in (B).  Proteins 
with a  described role in melanoma are labeled in blue, those with role in cancer proliferation or 
prognosis in green and those with a prometastatic role in red. 
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Next,   an overlap enrichment of the proteins downregulated upon LRP2 depletion 
and those overexpressed in UACC-62 shRAB7 (Figure 10A) was performed. This 
analysis allowed us to identified 16 proteins controlled by both LRP2 and RAB7 
(Figure 18B). This cluster was composed by proteins implicated in melanoma 
proliferation and metastasis such as CD59298, S100A4, S100A6298–300 and 
HSPA5301 among others (Figure 18C).  All together, these results expand the 
knowledge of vesicular trafficking in melanoma and have provided new insight in 
the regulation of sphingolipid metabolism. Moreover, we have identified a novel 
prometastatic target of RAB7, LRP2 that open new venues of research in the 
endolysosomal and cancer metastasis fields.
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Melanoma is prime example of aggressive tumor that proceeds with important changes 
in the transcriptome and proteome11,66,67,87,302.  Its incidence has increased worldwide 
becoming a public health problem(ref9 dire). Nevertheless, last decade has witnessed 
an enormous advance in genomic subclassification of melanoma patients attending to 
mutations in multiple signaling cascades (ie BRAF, NRAS, NF1, p53 and PTEN)55,87.  
However, unlike other tumors, melanoma subgroups do not present differences in 
patient prognosis303–305. 
 
Therefore, there is an urgent need to dissect the mechanisms of melanoma progression 
and metastasis. Our laboratory recently described a melanoma unique wiring of the 
lysosomal pathway that fosters tumor progression104. The small GTPase RAB7 was also 
identified as an early induced melanoma driver242 whose levels can be tuned to favor 
either proliferation or invasion104. Surprisingly, RAB7 regulation and expression in 
clinical specimens was unlike the small GTPase RAB27, a well-known target of 
MITF94,306–308 (the best characterized melanocyte lineage-specific transcription factor), 
that is involved in exosome secretion and melanoma metastasis74,243,309. 
 
The objective of this PhD thesis was to deepen the knowledge of the alterations of 
vesicular trafficking induced by RAB7 and RAB27 in melanoma and its implications in 
progression and metastasis. In brief, (1) we have confirmed previous studies describing 
that both small GTPases have similar roles in cell proliferation, but non-equivalent roles 
in cell invasion. (2) We have described differential vesicular trafficking alterations 
induced by either RAB7 or RAB27 silencing, particularly alterations in lysosomal 
biogenesis and motility. (3) An unbiased proteomic analysis of cell extracts us to identify 
a RAB7-dependent rewiring of the sphingolipid metabolism pathways characterized by 
an increase in ceramide production driven by the lysosomal proteins SMPD1 and GBA.  
(4) Accumulation of intracellular was responsible of the increase in invasion capacity 
upon RAB7 depletion in an auto- and paracrine manner. (5) In addition, proteomic 
characterization of the secretome changes induced by RAB7 silencing has identified a 
cluster of lysosomal proteins differentially secreted that were unaltered intracellularly. 
(6) From this cluster of proteins, we identified LRP2 as a novel melanoma prometastatic 
factor that was located in ceramide enriched exovesicles and increase melanoma cell 
invasiveness in an auto-and paracrine way. All together, we have unveiled how 
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melanomas modulate sphingolipid metabolism, increasing ceramide synthesis and 
inducing secretion of LRP2, a protein not associated with melanoma metastasis before 
in a RAB7 dependent manner. 
 
The figure 19 illustrates the findings of this PhD Thesis, highlighting the mechanism that 
mediating the increased melanoma metastasis observed upon RAB7 depletion. 
 
 
1. Non-equivalent roles of RAB7 and RAB27 in melanoma proliferation and 
invasion confirmed by proteomics 
 
RAB7 and RAB27 dependency of melanoma to has been previously addressed by us 
and other groups101,104.   However, even though they are the best characterized RAB 
Figure 19. Proposed model illustrating RAB7-dependent metastasis through ceramide and LRP2, 
Upon RAB7 downregulation, there, LRP2 is no longer degraded, therefore it is secreted via exovesicles 
produced by an increase in ceramide mediated by SMPD1 and GBA. This increased secretion of vesicles 
loaded with LRP2 increase invasive potential in a paracrine way. 
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proteins in this tumor type, we are the first ones comparing their effect in 
proliferation in parallel, both in vitro and in vivo, We also extended the previous 
knowledge associated with the role of these two RAB proteins in proliferation: In 
vitro, we have use an extensive panel of melanoma cell lines representative of the 
most frequent genetic background identified in patients. In vivo, we have employed 
a syngeneic melanoma mouse model that allowed us to rule out involvement of the 
immune system in the proliferation defects observed upon RAB7 or RAB27 silencing. 
We have determined that growth arrest is due to an A an impairment in S phase 
entry, which has been confirmed by our proteomics data, However, whether it is a 
direct or indirect effect needs to be further elucidated. Furtheremore, although both 
proteins are required for cell proliferation, RAB27 depletion, unlike RAB7 depletion, 
triggers apoptosis by inducing mitochondrial membrane depolarization and, 
therefore, growth arrest.    
 
In melanocytes, it has been shown that RAB7 and RAB27 control different steps in 
melanosome biogenesis and secretion232,310–312. Therefore, we initially hypothesized 
that RAB27 could be downstream RAB7 in promoting shRAB7 dependent increase in 
invasion capacity. However, this was not the case: Our proteomics experiment 
showed that vesicular trafficking pathways were modulated in different ways upon 
RAB7 or RAB27 depletion, and the observation was confirmed with Electron 
microscopy and lysoTracker fluorescent probes.  It is important to mention that 
intracellular alterations in membrane trafficking are later translated to the secretory 
phenotype and invasion capacity118,119.  We identified lysosomal alterations in the 
case of RAB7 depletion that promote melanoma invasiveness, but no with RAB27, 
actually enrichments in proteins secreted upon RAB27 depletion revealed pathways 
such as “proteasome” and “ER-stress” (Data not shown).   Together, this data suggest 
that RAB7 and RAB27 has different downstream effectors regulating different 
pathways that in the case of proliferation have the same result but different outputs 
in invasion. However, further characterization of the trafficking machinery is 
required in order to identify effectors of the phenotypes observed. 
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2. Implications of the rewiring of sphingolipid metabolism mediated by RAB7 
depletion  
 
One of the most relevant findings of this thesis was the identification of the rewiring 
of the sphingolipid metabolism pathways towards a ceramide production phenotype 
with implications in auto- and paracrine invasiveness. The proteomic approach 
employed identified the overexpression of SMPD1 and GBA, two lysosomal enzymes 
that produce more ceramide upon RAB7 depletion. Ceramide is one the best 
described inductor of apoptosis in cancer287,313,314, including melanoma315, and the 
mechanism of induction has been extensively described316.  
 
However, more recent evidence challenges this long-established anti-tumorigenic 
role of ceramide  and suggests it may favor tumor progression: In breast cancer there 
is an increase in  Ceramide Synthases (CERS) and ceramides have been observed 
during progression317. Ceramide originated by CERS6 protects from apoptosis  in 
HNSCC cells318  and in Hela cells, overexpression of CERS2 protects cells from 
ionizing radiation319. Regarding ceramide-induced autophagy, it can also be 
cytoprotective320,321, increase anoxia resistance322 and it is necessary for lung 
colonization in a melanoma mouse model of metastasis288.   Finally, ceramide also 
plays a role in vesicular trafficking: It regulates an ESCRT-independent mechanism 
of exosome secretion153,157, which might be behind increased LRP2 secretion in RAB7 
depleted cells. These exovesicles are enriched in ceramide compared to the parental 
cell line323.  
 
In our model, we ruled out that the increase in ceramide upon RAB7 depletion was 
triggering apoptosis. In line with the novel cancer-related ceramide function, it was 
very surprising to see that patients with the highest expression at RNA level of GBA 
or SMPD1 had worst prognosis than the rest. This might be a reflection of the lineage-
specific wiring of the lysosomal pathways in melanoma. SMPD1 and GBA are two 
lysosomal proteins; mutations in those genes have been associated with the 
lysosomal storage disorders Niemann-Pick disease (types A and B)324,325 and 
Gaucher disease284,326, respectively.  These two diseases together with CMTB2, 
disease caused by mutations  in RAB7 have in common the appearance of 
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neuropathies230,327–329. Moreover,  some subsets of patients suffering Gaucher 
disease or CMTB have  higher risk of developing cutaneous melanomas330–332, 
although whether this mutations could favor or hamper melanoma progression is 
unclear.  As melanocytes are cells from neural origin1, our data offer a mechanistic 
framework to close the gap between the melanoma-specific rewiring of vesicular 
trafficking and lysosomal storage diseases. 
 
Although a connexion of GBA and melanoma has not been previously addressed, the 
role of SMPD1 in melanoma is controversial: it is been regarded as tumor suppressor, 
whose depletion induces melanoma growth and metastasis113. Nevertheless, other 
study performed in a mouse model of melanoma metastasis, suggest that is 
important for in vivo colonization288. In our model, some of the effects observed upon 
RAB7 depletion, such as a decrease in cell proliferation and pigmentation (data not 
shown) matches with those described for SMPD1 overexpression113. However, upon 
RAB7 depletion there is an increase in the invasive potential, abolished upon 
siramesine or CBE treatment.  A possible reason of this difference, is because most of 
SMPD1 studies have been done with genetic downregulation or overexpression. 
However, in our model SMPD1 upregulation only occurs at protein level and not RNA 
level (data not shown) and in a more regulated location: the endo-lysosomal system. 
Actually, RAB7 is essential for lysosome biogenesis and its fusion with late 
endosomes and autophagosomes120,125,161,187. Therefore, the activity and turnover of 
lysosomal enzymes such as SMPD1 and GBA may be affected due to the impaired 
autophagic and endocytic flux and lysosomal biogenesis and homeostasis found 
upon RAB7 silencing124. Importantly, lysosomal membrane permeabilization can 
lead to the leakage of hydrolases and proteases into the cytoplasm leading to  
lysosomal mediated cell death289,333,334 interestingly, in macrophages,  SMPD1 
activity  is required for correct lysosome-endosome fusion335,336.  Therefore,  an 
increase in SMPD1 could  be a compensatory mechanism to alleviate lysosomal 
instability induced by RAB7 depletion337, an to avoid an excess in sphingomyelin 
levels, which can be deleterious for lysosomes338. Moreover, it is also required for the 
correct trafficking of MET receptor to the plasma membrane339 a tyrosine kinase 
with well described roles in drug resistance and cancer progression including 
melanoma74,340–342 . Thus, this study expands the knowledge of vesicular trafficking 
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by emphasizing its connection with ceramide production and reinforcing the non-
canonical apoptotic role of ceramide that results in a proinvasive phenotype in 
melanoma. 
 
3. Paracrine effect of Conditioned Medium in other cell types: LRP2 
 
Another striking finding is that cells treated with the CM of RAB7 or RAB27 depleted 
cells could recapitulate the changes in invasion observed in the donor cells. A similar 
effect has been described for other proteins such as LAMC2343, RAB3C291, RAB37292  
and miRNAs344 in several cancer models.  This induced increase in invasiveness is 
not a direct consequence of the increased levels of ceramide themselves, since 
addition of exogenous ceramide could not recapitulate the changes in invasiveness 
observed (data not shown). Thus, we hypothesized that the paracrine effect of 
shRAB7 derived conditioned medium could be mediated by a different process.  
 
Our lab and others have previously described that lysosomal proteins intracellular 
location can be regulated by RAB7 levels and translocated towards cell periphery 
and the extracellular space to favor metastasis104,237–239. However this conclusions 
were raised in the observation of individual proteins such as Cathepsins (refe 
direna) and XXX upon RAB7 depletion104. But no systemic assessment of changes in 
the secretome has been reported to date. However, we have performed an unbiased 
proteomic approach that led to the identification of a cluster of lysosomal proteins 
differentially secreted (without alterations in the intracellular fraction) upon RAB7 
depletion. Many of those genes have been, individually, shown to have a pro-
metastatic role in melanoma and other tumor types, such as SEMA3E345, CTSD346,347, 
MMP15348, and GM2A349. Surprisingly the top scoring gene in the proteomic analysis 
of the conditioned medium was not a protein with degradative or chemoattractant 
roles, but as transmembrane receptor: LRP2/Megalin. LRP2 expression has been 
described to increase along melanoma progression, and to have an essential role in 
melanoma cell proliferation296, results that were confirmed with our  Loss-of-
Function experiments and proteomic analysis. However, the positive effect here 
reported on metastatic or invasive potential of melanoma cells has not been 
previously observed. Curiously, RAB27 depletion also decreased LRP2 levels and 
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induced apoptotic cell death, suggesting that LRP2 may be downstream RAB7 and 
RAB27 but modulated in a different manner. 
 
 LRP2 is expressed during embryonic development in the neural tube, where it plays 
a role in forming brain structures295,350,351.  In adults, LRP2 expression is generally 
restricted to the proximal tubes of the kidney, where it mediates the clearance  of 
filtered molecules352,353. Interestingly, this protein has been identified in urine-
derived exosomes354 and altered expression of LRP2 has been described in several 
nephropathies355,356 and neuropathies, such as Alzheimer Disease357,358. Curiously, 
although little is known about the mechanism of LRP2 intracellular trafficking, 
LRP2-mediated endocytosis has been described as an alternative pathway for 
lysosomal biogenesis359. LRP2 expression is widespread during embryonic 
development  and later repressed360 this switch resembles EMT process which is 
crucial for the reestablishing of migratory abilities in cancer cells. Alterations in 
LRP2 expression levels or mutational status have been identified in several tumor 
types such as: hepatocellular carcinoma361, renal362, prostate cancer363 and 
Melanoma296. However, only in the melanoma study, functional experiments to 
address the physiological relevance of LRP2 were performed.  Thus, the role of LRP2 
in cancer is mostly unknown. 
 
We have shown  that LRP2 is  secreted in melanoma-derived exosomes356, which are 
small vesicles with crucial roles in metastasis74,364,365  and derived from RAB7 
regulated late endosomes (Multivesicular bodies)187,366. Those exosomes can be 
uptaken by recipient cells and their content (RNA and proteins) can confer changes 
in invasiveness367–370 to the recipient cells.  LRP2 has been identified in exovesicles  
purified from urine samples obtained from healthy354,371,372, diabetic patients356 or 
kidney cells in culture373,  although, this studies were descriptive and provide no 
mechanism of how is LRP2 translocated to the exosomes. Interestingly, LRP2 
transmembrane domain has been described to be associated with lipid rafts in 
Madin-Darby canine kidney cells374. Lipid rafts are membrane microdomains, with 
important functions in cell signaling375. They are composed by several species of 
glycosphingolipids and glycoprotein, being ceramide one of them376,377. Thus, our 
data suggest that upon ceramide formation blockage with Siramesine or CBE, 
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ceramide abundance in lipid rafts is diminished and LRP2 can no longer be directed 
there. This suggest a novel mechanism of LRP2 regulation. 
 
LRP2 is a  transmembrane receptor with more than 50 ligands described so far294. 
However, there is nothing described regarding how can this protein increase cell 
invasion in a paracrine way. One hypothesis that may explain how LRP2 can increase 
invasiveness of other  melanoma cells, would propose that LRP2 has a mechanism 
of action similar to Notch112,358: LRP2 can be cleaved in a process called regulated 
intramembrane proteolysis(RIP)378, and the resulting intracellular cytoplasmic 
domain (ICD)  might be translocated to the nucleus where it would alter gene 
expression115,358,379. Actually, a Notch-similar mechanism of action has been 
described for LRP1380,381, another member of the LDLR family  
 
4. Future Perspectives 
 
The work This thesis has shed light about a novel mechanism of vesicular trafficking 
modulation exploited by tumor cells to metastasize: RAB7dependent rewiring of 
sphingolipid metabolism to increase ceramide production and secretion in 
exovesicles loaded with LRP2, that in turn promotes tumor progression in a 
paracrine way. Still, future work directed at better understanding the crosstalk 
between vesicular trafficking regulators and lipid metabolism and cancer will extend 
our knowledge of the contribution of these processes to human disease. 
 
RAB proteins are general regulators of vesicular trafficking, acting as protein hubs 
for the binding of downstream interactors. Further analyses regarding the role of 
particular effectors downstream RAB7 are needed to understand how lysosomes 
move towards cell periphery and secrete their content into the extracellular space. 
Also, a deeper study of how is ceramide trafficked through the endolysosomal 
system, and its regulation on LRP2 protein levels, will broad our knowledge of the 
connection between vesicular trafficking and sphingolipid metabolism. 
 
It should be noted that many groups have found associations between neural 
diseases such as Parkinson382,383, Alzheimer384 and melanoma. Importantly, 
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mutations in SOX10, the upstream regulator of RAB7 expression are also implicated 
in demyelinating peripheral neuropathies385. These diseases are characterized by 
the loss of the myelin sheath that insulates the nerves, of which sphingolipids are an 
essential component386. Our data link specific rewiring of vesicular trafficking 
pathways with altered sphingolipid metabolism, specifically, processes that take 
place in the lysosomes. Therefore, it would be interesting to explore whether GBA or 
SMPD1 have an implication in neuropathies or could play a driver role in in the 
progression of melanomas developed by patients suffering from Lysosomal storage 
diseases. 
 
Regarding the rewiring of sphingolipid metabolism, there are other lipids and 
enzymes with important prometastatic functions such as Sphingosine 1 Phosphate 
(S1P)387–389 or ASAH1390. Whether they might be playing a role in RAB7 dependent 
invasion is unknown. In order to obtain a more complete picture of the sphingolipid 
metabolism rewiring directed by RAB7 depletion.  ASAH1, S1P and CERS activity 
should be taken into account.  
 
Finally, there are many questions pending regarding LRP2 regulation, function and 
intracellular trafficking in melanoma. Therefore, a better understanding in all these 
topics will provide a meaningful insight about the mechanism of melanoma 
metastasis that might have the potential to be exploited as therapeutic target.  
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In the light of the results presented in this PhD thesis, we can conclude the 
following: 
 
1. RAB7 and RAB27 expression are essential for melanoma cell proliferation 
but have non-equivalent roles in cell invasion. 
 
2. RAB7 and RAB27 depletion induce differential vesicular trafficking 
alterations: while RAB7 knockdown causes an increase in the number of 
lysosomes and their shift towards the cell periphery, RAB27 silencing 
induces membrane disruption and microvesicles formation. 
 
3. An unbiased proteomic approach allowed for the identification of the 
sphingolipid metabolism rewiring towards ceramide production upon 
RAB7 depletion. This switch is characterized by an increase in SMPD1 and 
GBA protein levels. 
 
4. In melanoma, the increase in ceramide content does not cause cell death 
but instead promotes cell invasion in a RAB7 dependent manner. 
 
5. Proteomic analysis of the secreted fraction upon RAB7 depletion allowed 
for the identification of a cluster of lysosomal proteins specifically secreted 
(showing no changes in the intracellular levels). 
 
6. LRP2, identified in the secreted lysosomal proteins cluster, is essential for 
melanoma proliferation and mediates RAB7 dependent invasion. It is 
secreted in exovesicles and colocalizes with ceramide-enriched domains. 
 
Collectively the data presented in this PhD thesis deepens the knowledge of 
vesicular trafficking in melanoma and establish a novel crosstalk between 
sphingolipid metabolism and vesicle trafficking modulators.
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A luz de los resultados presentados en esta tesis doctoral, se presentan las 
siguientes conclusiones: 
 
1. La capacidad proliferativa de las células de melanoma es dependiente de la 
expresión tanto de RAB7 como de RAB27. Sin embargo, el silenciamiento 
de ambos genes tiene un efecto contrapuesto en la capacidad invasiva 
celular. 
 
2. El silenciamiento de RAB7 o RAB27 desencadena una serie de alteraciones 
citoplásmicas. Una reducción en los niveles de RAB7 produce un 
incremento en la producción de lisosomas y su translocación a la periferia 
celular. Mientras que el silenciamiento de RAB27 presenta un cambio 
fenotípico caracterizado por la disrupción de la membrana y la formación 
de microvesículas. 
 
3. Un análisis objetivo del proteoma celular tras el silenciamiento de RAB7 ha 
permitido la identificación de alteraciones en el metabolismo de 
esfingolípidos. Esta modulación está caracterizada por el incremento en los 
niveles tanto de SMPD1 como de GBA, ambas enzimas esenciales para la 
producción de ceramida. 
 
4.  El incremento en ceramida no modula la muerte celular, no obstante, 
conlleva a un aumento en la capacidad invasiva de las células de melanoma 
dependiente de la expresión de RAB7.  
 
5. Mediante un análisis proteómico del medio condicionado controlado por la 
expresión de RAB7 se ha identificado un aumento en la secreción de un 
grupo de proteínas lisosomales. Dicho cambio no se observa sin embargo a 
nivel intracelular. 
 
6. Análisis funcionales tras la identificación de LRP2 en el medio 
condicionado, revelan su papel indispensable en el mantenimiento de la 
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proliferación en melanoma. Además, postulan a LRP2 como nuevo factor 
de metástasis controlado por la expresión de RAB7. 
 
Los datos presentados en esta tesis aumentan nuestro conocimiento del papel del 
tráfico vesicular en melanoma mediante el establecimiento de un nuevo punto de 
conexión entre el metabolismo de esfingolípidos y los moduladores del tráfico 
vesicular. 
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UPREGULATED PROTEINS shRAB7/shControl 
DOWNREGULATED PROTEINS 
 shRAB7/shControl 
Annex 1.  List of proteins regulated in melanoma cell lines upon RAB7 (in both cell 
lines, SK-MEL-103 UACC-62) with fold change values. Pink: upregulated genes, green: 
downregulated genes.  
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DOWNREGULATED PROTEINS shRAB27/shControl 
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DOWNREGULATED PROTEINS shRAB27/shControl 
Annex 2.  List of proteins 
regulated in melanoma cell 
lines upon RAB27 (in both 
cell lines, SK-MEL-103 
UACC-62) with fold change 
values. Pink: upregulated 
genes, green: downregulated 
genes.  
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Annex 3.  Enriched biological processes 
identified from changes in the Proteome of the 
indicated cell lines defined by KEGG database  
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Figure S1.  Schematic representation of sphingolipid metabolism.  De novo synthesis 
pathway of ceramide, (blue). Synthesis/degradation of glucosylceramides (green/light 
blue) and sphingomyelin (orange/purple). Ceramide degradation (red). Diseases associated 
with enzymes mutations are depicted in gray boxes. Ref314 
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Annex 5.  List of genes regulated in each Gene Ontology Terms found to be 
significantly enriched in UACC-62 shRAB7 specifically secreted proteins.  
 
 
